US20140275165A1 - COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY - Google Patents
COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY Download PDFInfo
- Publication number
- US20140275165A1 US20140275165A1 US14/223,967 US201414223967A US2014275165A1 US 20140275165 A1 US20140275165 A1 US 20140275165A1 US 201414223967 A US201414223967 A US 201414223967A US 2014275165 A1 US2014275165 A1 US 2014275165A1
- Authority
- US
- United States
- Prior art keywords
- compound
- cell
- nfκb
- compounds
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 304
- 230000000694 effects Effects 0.000 title claims abstract description 63
- 102100021257 Beta-secretase 1 Human genes 0.000 title claims abstract description 47
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 title claims abstract description 13
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims abstract description 84
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 38
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 230000004054 inflammatory process Effects 0.000 claims abstract description 14
- 206010061218 Inflammation Diseases 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 12
- 230000004064 dysfunction Effects 0.000 claims abstract description 12
- 210000000987 immune system Anatomy 0.000 claims abstract description 10
- 230000004663 cell proliferation Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 67
- -1 2-Nitrophenyl Chemical group 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 26
- 230000005937 nuclear translocation Effects 0.000 claims description 22
- 230000005764 inhibitory process Effects 0.000 claims description 21
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 238000003776 cleavage reaction Methods 0.000 claims description 15
- 230000007017 scission Effects 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 108010057466 NF-kappa B Proteins 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 6
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 6
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 6
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 102000003945 NF-kappa B Human genes 0.000 claims description 5
- 150000001356 alkyl thiols Chemical class 0.000 claims description 5
- 150000001504 aryl thiols Chemical class 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims 3
- 238000011282 treatment Methods 0.000 abstract description 24
- 230000004770 neurodegeneration Effects 0.000 abstract description 9
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 7
- 230000000670 limiting effect Effects 0.000 description 72
- 238000003556 assay Methods 0.000 description 58
- 238000000099 in vitro assay Methods 0.000 description 46
- 230000001225 therapeutic effect Effects 0.000 description 41
- 101710150192 Beta-secretase 1 Proteins 0.000 description 38
- 230000009467 reduction Effects 0.000 description 34
- FEBBZFJWAMUFPI-UHFFFAOYSA-N n-quinolin-8-ylbenzenesulfonamide Chemical class C=1C=CC2=CC=CN=C2C=1NS(=O)(=O)C1=CC=CC=C1 FEBBZFJWAMUFPI-UHFFFAOYSA-N 0.000 description 25
- 230000002596 correlated effect Effects 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 21
- 230000006641 stabilisation Effects 0.000 description 20
- 238000011105 stabilization Methods 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 19
- 108060001084 Luciferase Proteins 0.000 description 18
- 239000005089 Luciferase Substances 0.000 description 18
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 16
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 210000003618 cortical neuron Anatomy 0.000 description 15
- 0 [1*]C1=NC2=C(NS([10*])(=O)=O)C=C([5*])C([4*])=C2C([3*])=C1[2*] Chemical compound [1*]C1=NC2=C(NS([10*])(=O)=O)C=C([5*])C([4*])=C2C([3*])=C1[2*] 0.000 description 14
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 13
- 239000006143 cell culture medium Substances 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 9
- 238000004020 luminiscence type Methods 0.000 description 9
- 230000036515 potency Effects 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 210000002243 primary neuron Anatomy 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 6
- 241000713666 Lentivirus Species 0.000 description 6
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 6
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 108090000204 Dipeptidase 1 Proteins 0.000 description 5
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 102000006635 beta-lactamase Human genes 0.000 description 5
- 238000000423 cell based assay Methods 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229960003722 doxycycline Drugs 0.000 description 5
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 5
- 238000005462 in vivo assay Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000005580 one pot reaction Methods 0.000 description 5
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000005556 structure-activity relationship Methods 0.000 description 5
- 229940124530 sulfonamide Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 241000254173 Coleoptera Species 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 102100035100 Transcription factor p65 Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004900 c-terminal fragment Anatomy 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000010228 ex vivo assay Methods 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- NIOOKXAMJQVDGB-UHFFFAOYSA-N 2-amino-n-quinolin-8-ylbenzenesulfonamide Chemical compound NC1=CC=CC=C1S(=O)(=O)NC1=CC=CC2=CC=CN=C12 NIOOKXAMJQVDGB-UHFFFAOYSA-N 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 3
- 101000979338 Homo sapiens Nuclear factor NF-kappa-B p100 subunit Proteins 0.000 description 3
- 102100022219 NF-kappa-B essential modulator Human genes 0.000 description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 3
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 description 3
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 3
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000006193 diazotization reaction Methods 0.000 description 3
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 102000044297 human BACE1 Human genes 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- YZPOQCQXOSEMAZ-UHFFFAOYSA-N pbt2 Chemical compound ClC1=CC(Cl)=C(O)C2=NC(CN(C)C)=CC=C21 YZPOQCQXOSEMAZ-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- MBSAWVJPVWNOBN-UHFFFAOYSA-N 6-methoxy-2-methylquinolin-8-amine Chemical compound N1=C(C)C=CC2=CC(OC)=CC(N)=C21 MBSAWVJPVWNOBN-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 101000736088 Homo sapiens PC4 and SFRS1-interacting protein Proteins 0.000 description 2
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 108010014632 NF-kappa B kinase Proteins 0.000 description 2
- 101710090077 NF-kappa-B essential modulator Proteins 0.000 description 2
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 206010045240 Type I hypersensitivity Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
- 208000036815 beta tubulin Diseases 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960005228 clioquinol Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 102000046783 human APP Human genes 0.000 description 2
- 102000047410 human NFKB1 Human genes 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001690 micro-dialysis Methods 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000009959 type I hypersensitivity Effects 0.000 description 2
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- YAZSBRQTAHVVGE-UHFFFAOYSA-N 2-aminobenzenesulfonamide Chemical compound NC1=CC=CC=C1S(N)(=O)=O YAZSBRQTAHVVGE-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- GNDKYAWHEKZHPJ-UHFFFAOYSA-N 2-nitrobenzenesulfonimidic acid Chemical compound NS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O GNDKYAWHEKZHPJ-UHFFFAOYSA-N 0.000 description 1
- PGOHIRZWBFOSRW-UHFFFAOYSA-N 2-thiophen-2-ylquinazoline Chemical class C1=CSC(C=2N=C3C=CC=CC3=CN=2)=C1 PGOHIRZWBFOSRW-UHFFFAOYSA-N 0.000 description 1
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- HEVNLMSJUFKWBS-UHFFFAOYSA-N 4-methyl-2-nitrobenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C([N+]([O-])=O)=C1 HEVNLMSJUFKWBS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 101150058765 BACE1 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ICYRASHWAHRIER-UHFFFAOYSA-N C1=CC=CC2=NC(NS(=O)=O)=CC=C21 Chemical class C1=CC=CC2=NC(NS(=O)=O)=CC=C21 ICYRASHWAHRIER-UHFFFAOYSA-N 0.000 description 1
- MXKZFNJSAXLWNC-UHFFFAOYSA-N CC1=CC=C2C=CC3=C(NS(=O)(=O)C4=C3C=C(C(F)(F)F)C=C4)C2=N1 Chemical compound CC1=CC=C2C=CC3=C(NS(=O)(=O)C4=C3C=C(C(F)(F)F)C=C4)C2=N1 MXKZFNJSAXLWNC-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101001002507 Mus musculus Immunoglobulin-binding protein 1 Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- QECVIPBZOPUTRD-UHFFFAOYSA-N N=S(=O)=O Chemical group N=S(=O)=O QECVIPBZOPUTRD-UHFFFAOYSA-N 0.000 description 1
- RRBLHSDHBNSINM-UHFFFAOYSA-N NC1=C(S(=O)(=O)NC2=C3N=CC=CC3=CC=C2)C=CC(C(F)(F)F)=C1 Chemical compound NC1=C(S(=O)(=O)NC2=C3N=CC=CC3=CC=C2)C=CC(C(F)(F)F)=C1 RRBLHSDHBNSINM-UHFFFAOYSA-N 0.000 description 1
- LBGHJHSHSPLNRI-UHFFFAOYSA-N O=S(=O)(NC1=C2N=CC=CC2=CC(Br)=C1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=S(=O)(NC1=C2N=CC=CC2=CC(Br)=C1)C1=CC2=CC=CC=C2C=C1 LBGHJHSHSPLNRI-UHFFFAOYSA-N 0.000 description 1
- CELCJNIQYYQLHB-UHFFFAOYSA-N O=S1(=O)NC2=C(C=CC3=CC=CN=C32)C2=C1C=CC(C(F)(F)F)=C2 Chemical compound O=S1(=O)NC2=C(C=CC3=CC=CN=C32)C2=C1C=CC(C(F)(F)F)=C2 CELCJNIQYYQLHB-UHFFFAOYSA-N 0.000 description 1
- 108010062618 Oncogene Proteins v-rel Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038802 Reticuloendothelial system stimulated Diseases 0.000 description 1
- 238000005614 Skraup synthesis reaction Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 102000004380 Transcription factor RelB Human genes 0.000 description 1
- 108090000952 Transcription factor RelB Proteins 0.000 description 1
- RPBWZBPLNQWXMX-UHFFFAOYSA-N [C].N1=CC=CC2=CC=CC=C21 Chemical compound [C].N1=CC=CC2=CC=CC=C21 RPBWZBPLNQWXMX-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 1
- 229940069510 parthenolide Drugs 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000011663 regulation of signaling Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000002805 secondary assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001149 thermolysis Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to compounds with activity as NF ⁇ B inhibitors.
- the present invention also relates to methods for treating, preventing, and/or ameliorating diseases related to dysfunction of cell proliferation, the immune system, inflammation and/or neurodegeneration using such compounds or pharmaceutical compositions comprising such compounds.
- Nuclear factor- ⁇ B (NF ⁇ B) signaling is an essential signal transduction pathway involved in inflammatory responses, oncogenesis, viral infection, the regulation of cell proliferation and apoptosis and, in particularly in the case of B and T lymphocytes, in antigenic stimulation (Ghosh, 1998, Annu. Rev. Immunol., 16, 225-260; Karin, 1999, J. Biol. Chem., 274, 27339-27342; Israel, 2000, Trends Cell. Biol., 10, 129-133; Santoro, 2003, EMBO J., 22, 2552-2560).
- NF ⁇ B In mammalian cells, there are five NF ⁇ B family members that dimerize: RelA, RelB, c-Rel, NF ⁇ B 2/p100/p52 and NF ⁇ B 1/p105/p50.
- NF ⁇ B whose predominant form is a heterodimeric transcription factor composed of p50 and RelA subunits, remains sequestered in the cytoplasm through association with members of an inhibitory family of proteins known as I ⁇ B.
- IKK IkB kinase complex
- IKK ⁇ and IKK ⁇ exhibit striking structural similarity (52%), genetic studies have shown that they are involved in two pathways for the activation of NF ⁇ B (Pomerantz, 2002, Molecular Cell 2002 10: 693-695). IKK ⁇ has been identified as the pro-inflammatory kinase responsible of activation of classical NF ⁇ B complexes, whereas IKK ⁇ in association with NF ⁇ B inducing kinase (NIK) plays an essential role in the non-canonical NF ⁇ B signaling pathway (Senftleben, 2001, 293: 1495-1499).
- NF ⁇ B plays an essential role in the development and progression of cancer, including breast cancer.
- Animal studies suggest the presence of constitutively active NF ⁇ B at an early stage during neoplastic transformation of mammary cells (Clarkson et al., 2000, J Bio Chem. 275(17):12737-42).
- NF ⁇ B inhibits apoptosis in mouse mammary epithelia (Soy ak et al., 1999, Cell Growth Differ. 10(8):537-44) and selective activation of NF ⁇ B subunits have been found in human breast cancer cell lines and patient samples (Sovak et at, 1997, J Clin Invest.
- NF ⁇ B inhibitor parthenolide
- the Mullerian inhibiting substance was also found to inhibit breast cancer growth through NF ⁇ B mediated pathway (Segev et al., 2000, J Bio Chem. 275(37):28371-9).
- the transactivation function of NF ⁇ B is negatively regulated by IKI411 in breast cancer cell lines (Newton et al., 1999, J Bio Chem. 274(26):18827-35).
- HER2neu can activate NF ⁇ B through the activation of Akt pathway and block apoptosis (Zhou et al., 2000, J Bio Chem. 275(10:8027-31). All these reports together suggest that NF ⁇ B plays an important role in cancer generally and in breast cancer specifically.
- NF ⁇ B activation represents a target for development of new anti-inflammatory and anti-cancer drugs (Poulaki, 2002, Am J Pathol. 161: 2229-2240).
- IKK complex represents one of the most promising molecular targets for discoveries of new specific NF ⁇ B inhibitors.
- therapeutic success will greatly depend on the abilities of the NF ⁇ B inhibitors to block activating signals without modifying the basal level of NF ⁇ B activity. For example, May et al.
- the present invention relates to compounds which inhibit NF ⁇ B activity.
- the compounds of the invention may be used to inhibit NF ⁇ B activity in a subject, or in a cell in culture.
- the present invention also provides a method for the treatment of a dysfunction of cell proliferation, the immune system and/or inflammation in an individual, wherein the dysfunction is associated with NF ⁇ B activity, by administering to an individual in need of such treatment a pharmaceutical composition comprising at least one compound of Formulas I-III in an amount effective to treat the dysfunction.
- the present invention relates to a compound of Formula I:
- the present invention relates to a compound of Formula II:
- the present invention relates to a compound of Formula III:
- the present invention also provides a method of inhibiting the activity of NF ⁇ B, by contacting the NF ⁇ B, an NF ⁇ B associated protein, or a cell expressing NF ⁇ B, with at least one compound of Formulas I-III (meaning Formula I, Formula II, or Formula III) in an amount effective to inhibit the activity of NF ⁇ B.
- the NF ⁇ B is expressed by a cell, for example, a mammalian cell, and the cell is contacted with an effective amount of at least one compound of Formulas I-III.
- the NF ⁇ B, or cell expressing NF ⁇ B is contacted with an effective amount of at least one compound of Formulas I-III in vitro.
- the pharmaceutical composition may optionally be used in conjunction with one or more additional compound for the treatment of a dysfunction of cell proliferation, the immune system and/or inflammation.
- BACE1 an enzyme that participates in the production of A ⁇ .
- a ⁇ has been linked to neurodegeneration and to Alzheimer's Disease in particular, such compounds may be used in the treatment of neurodegenerative conditions and in particular in Alzheimer's Disease and related conditions.
- FIG. 1A-B depicts general structure of N-(quinolin-8-yl)benzenesulfonamides. A) Open chain and B) cyclized structures.
- FIG. 2 depicts a method for synthesizing a particular compound of Formula II (the particular compound identified as compound 9) and a particular compound of formula III (the particular compound identified as compound I).
- FIG. 3A-B depicts (A) a one-pot synthesis reaction mechanism synthesizing compound 9a of Formula II and compound I a of Formula III. (B) depicts the synthesis of particular compounds of Formula II (the particular compounds identified as 9i, 9j, and 9k).
- FIG. 4 depicts a one-pot synthesis reaction mechanism for converting particular compounds of Formula II into particular compounds of Formula III.
- the particular R groups of the starting compounds (9a-p) and the corresponding synthesized compounds (1a-p) are identical in each synthesis, and are illustrated in the table along with the individual yields of compounds 1a-p.
- FIG. 5A-B depicts (A) The two-color dual luciferase based assay.
- I ⁇ B ⁇ is fused to a luciferase emitting greenlight (CBG68), while a red light-emitting luciferase (CBR) is present in its native state.
- CBG68 luciferase emitting greenlight
- CBR red light-emitting luciferase
- Both luciferases are regulated by binding of the tet repressor to the tet operator (TO) binding site (TO), allowing simultaneous induction of the luciferases by the CMV promoter upon addition of doxycycline and test compounds.
- the CBR protein serves to normalize for non-specific effects, while the levels of the I ⁇ B ⁇ -CBG68 protein increase uniquely with inhibition of the NF ⁇ B pathway leading to I ⁇ B ⁇ degradation.
- TNF ⁇ stimulation results in nuclear translocation of NF ⁇ B, which is detected by immunofluorescence using an anti-p65 antibody and a secondary antibody labeled with an Alexa 647 fluorophore (A647).
- FIG. 6 depicts several compounds identified by the NFkB inhibition screens illustrated in FIG. 4 , including Structures of MG-132 (1), BAY11-7082 (2), a quinazoline based inhibitor of AP1 and NF ⁇ B mediated transcription (3), N-(quinolin-8-yl)benzenesulfonamide; PubChem CID: 161167 (4), and C7-locked N-(quinolin-8-yebenzenesulfonamide (5); PubChem CID: 659101.
- FIG. 7A-D depicts the NF ⁇ B inhibitory effect achieved by exemplary compounds of Formulas I and III in three cell-based NF ⁇ B activity assays.
- FIGS. 7A and C show the inhibitory effect of the compounds as measured by an I ⁇ B ⁇ stabilization assay, NF ⁇ B nuclear-translocation assay, and NF ⁇ B-bla expression assay.
- I ⁇ B ⁇ stabilization assay a higher efficacy of I ⁇ B ⁇ stabilization compared to stabilization achieved by MG-132 (an I ⁇ B ⁇ stabilizing agent) indicates greater NF ⁇ B inhibition.
- I ⁇ B ⁇ stabilization was measured as an increase in luminescence of a green luciferase I ⁇ B ⁇ construct.
- Stabilization at a lower EC 50 concentration further indicates more potent NF ⁇ B inhibition.
- a red luciferase under the same regulatory control as the I ⁇ B ⁇ construct was used as a control to monitor cell uniformity and non-specific effects.
- Compounds that stabilized I ⁇ B ⁇ were those that increased green luminescence with minimal effects on red luminescence.
- FIG. 7B shows the synthetic scheme used to generate compounds 6-18 and 23-28 of Formula I.
- FIG. 7D shows the synthetic scheme used to generate compounds 19-22 of Formula I and compounds 28-40 of Formula III.
- FIG. 8 depicts a sAPP ⁇ assay utilized to identify inhibitors of BACE1.
- the assay utilizes SY5Y cells stably overexpressing BACE-GFP and SEAP-APPwt. Cells are incubated with a candidate compound for 6 hours prior to harvesting media. BACE1-mediated cleavage of APP results in the release of sAPP ⁇ into the media. ⁇ -secretase, a competing enzyme that is non-amyloidogenic, also cleaves APP to release sAPP ⁇ . Using an sAPP ⁇ -specific antibody (s ⁇ wt), SEAP-sAPP ⁇ is specifically captured in a modified ELISA assay. Detection is achieved by addition of the fluorescent alkaline phosphatase substrate, 4-methylumbelliferyl phosphate (4-MUP).
- 4-MUP 4-methylumbelliferyl phosphate
- FIG. 9A-B depicts a targeted screen of N-(quinolin-8-yl)benzenesulfonamides, a small-scale screen using 176 structurally-related compounds based on the scaffold of N-(quinolin-8-yl)benzenesulfonamides.
- FIG. 10A-B depicts SAR studies of N-(quinolin-8-yl)benzenesulfonamides. 28 full and partial hits, shown in (A) for compounds 1-26 and (B) for compounds 27 and 28, from the targeted screen of N-(quinolin-8-yl)benzeriesulfonamides were characterized in SY5Y-BACEGFP-SEAPAPPwt cells using the cell-based BACE1 assay. All compounds were tested at 8 concentrations (30, 10, 3, 1, 0.3, 0.1, 0.03, and 0.01 ⁇ M), and data points were analyzed with Origin software and fitted using a logistic model for IC 50 determination.
- FIG. 11A-B depicts Lentiviral-mediated transduction of APPsw in primary neurons.
- Primary cortical neurons were harvested from wild-type P0 mice and cultured according to established protocols.
- Lentivirus harboring human Swedish mutant APP (Lenti-APPsw) was packaged using ViraPower Lentiviral Packaging mix (Invitrogen) according to the manufacturer's protocol.
- DIV-14 neurons were incubated for 24 hours with primary culture media containing the indicated volume (in ⁇ l) of virus (LV-1 and LV-2 denote 2 separate batches of virus, 0 denotes no virus was used). After infection, neurons were incubated for 72 hours with primary culture media. Media was collected for A ⁇ 40 ELISA (BioSource), and cell lysates were probed with APPCT antibody to visualize transduced full-length APP.
- A Bar graph depicting results
- B Assay results.
- FIG. 12 depicts immunocytochemistry of primary cortical neurons.
- DIV-14 primary cortical neurons from wild-type mice were fixed, permeabilized, and stained with TUT I to visualize neuronal ⁇ -tubulin (green).
- Cell nuclei (blue) were visualized with a DAPI co-stain.
- Cells were imaged with the Nikon C1 digital confocal system at 60 ⁇ magnification.
- FIG. 13A-B depicts the effect of CU-264 on A ⁇ expressing primary cortical neuron cultures from wild-type mice transformed with lentivirus harboring APPsw.
- CU-264 which exhibited sub-micromolar potency for sAPP ⁇ reduction in SY5Y-BACEGFP-SEAPAPPwt cells, does not reduce A ⁇ 40 levels in primary neurons when the cells are incubated with 2 ⁇ M CU-264. At 10 ⁇ M, CU-264 increased A ⁇ levels.
- A Bar graph depicting results;
- B Assay results.
- the NF ⁇ B is a human NF ⁇ B.
- the NF ⁇ B is preferably, but not by way of limitation, encoded by the Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NF ⁇ B1) (GenBank accession number NM — 003998), Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) (NF ⁇ B2) (GenBank accession numbers NM — 001077493, NM — 001077494, or NM — 002502), Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog A (avian) (RELA) (GenBank accession number NM — 021975), Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B (RELB) (GenBank accession number NM — 00
- NF ⁇ B can be encoded by any nucleic acid molecule exhibiting at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or up to 100% homology to any one of the NF ⁇ B genes (as determined by standard software, e.g. BLAST or FASTA), and any sequences which hybridize under stringent conditions to these sequences, which retain NF ⁇ B activity.
- standard software e.g. BLAST or FASTA
- an NF ⁇ B of the invention may be characterized as having an amino acid sequence described by GenBank accession numbers: NP — 003989, NP — 001070961, NP — 001070962, NP — 002493, NP — 068810, NP — 006500, and NP — 002899, or any other amino acid sequence at least 90% homologous thereto which retains NF ⁇ B activity.
- NF ⁇ B comprises a family of proteins which includes, but is not limited to, the proteins NF ⁇ B1 (p50), NF ⁇ B2 (p52), RelA (p65), RelB and c-Rel.
- the BACE1, NF ⁇ B or APP may be a recombinant BACE1, NF ⁇ B or APP polypeptide encoded by a recombinant nucleic acid, for example, a recombinant DNA molecule, or may be of natural origin.
- NF ⁇ B function of the immune system refers to any irregular activation of the innate and adaptive immune response associated with an increase in NF ⁇ B activity, for example, aberrant T-cell or B-cell development, maturation, and/or proliferation.
- a disease associated with inflammation encompasses both acute responses (i.e., responses in which the inflammatory processes are active) as well as chronic responses (i.e., responses marked by slow progression and formation of new connective tissue).
- a disease associated with inflammation that is to be treated by a compound of the instant invention is, by way of example, but not by way of limitation, type I hypersensitivity, atopy, anaphylaxis, asthma, osteoarthritis, rheumatoid arthritis, septic arthritis, gout, juvenile idiopathic arthritis, still's disease, ankylosing spondylitis, inflammatory bowel disease, Crohn's disease or inflammation associated with vertebral disc herniation.
- alkyl refers to a straight or branched C 1 -C 20 , preferably C 1 -C 5 , hydrocarbon group consisting solely of carbon and hydrogen atoms, containing no unsaturation, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl).
- alkenyl refers to a C 2 -C 20 , preferably C 1 -C 5 , aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be a straight or branched chain, e.g., ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl
- cycloalkyl denotes an unsaturated, non-aromatic mono- or multicyclic hydrocarbon ring system such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
- multicyclic cycloalkyl groups include perhydronapththyl, adamantyl and norbornyl groups bridged cyclic group or sprirobicyclic groups, e.g., Spiro (4,4) non-2-yl.
- aryl refers to aromatic radicals having in the range of about 6 to about 14 carbon atoms such as phenyl, naphthyl, tetrahydronapthyl, indanyl, biphenyl.
- heterocyclic refers to a stable 3- to 15-membered ring radical which consists of carbon atoms and one or more, for example, from one to five, heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
- the heterocyclic ring radical may be a monocyclic or bicyclic ring system, which may include fused or bridged ring systems, and the nitrogen, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states.
- a nitrogen atom, where present, may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e., heteroaromatic or heteroaryl aromatic).
- the heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
- heteroaryl refers to a heterocyclic ring wherein the ring is aromatic.
- the substituents in the ‘substituted alkyl’, ‘substituted alkenyl’, ‘substituted cycloalkyl’, ‘substituted aryl,’ ‘substituted heteroaryl’ ‘substituted alkoxy,’ ‘substituted aryloxy,’ ‘substituted alkylthiol,’ and ‘substituted arylthiol’ may be the same or different, with one or more selected from the groups hydrogen, halogen, acetyl, nitro, oxo ( ⁇ O), CF 3 , NH 2 , OCH 3 , or optionally substituted groups selected from alkyl, alkoxy and aryl.
- halogen refers to radicals of fluorine, chlorine, bromine and iodine.
- BACE 1 refers to a polypeptide which mediates the cleavage of APP in the ⁇ -amyloidgenic pathway, producing an sAPP ⁇ ectodomain APP metabolite, which is released into the extracellular space, and an intracellular C-terminal fragment (CTF).
- the BACE1 is a human BACE1.
- the BACE1 is preferably encoded by the Homo sapiens beta-site APP-cleaving enzyme 1 (BACE1) gene (GenBank accession numbers NM — 012104, NM — 138972, NM — 138971, or NM — 138973), or any nucleic acid which encodes a human BACE1 polypeptide.
- BACE1 can be encoded by any nucleic acid molecule exhibiting at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or up to 100% homology to a BACE1 gene (as determined by standard software, e.g. BLAST or FASTA), and any sequences which hybridize under stringent conditions to these sequences which retain BACE1 activity, where stringent conditions are as described in U.S. Published Patent Application US20030082140, which is hereby incorporated by reference in its entirety and for all purposes.
- standard software e.g. BLAST or FASTA
- a BACE1 of the invention may be characterized as having an amino acid sequence described by GenBank accession numbers: NP — 036236, NP — 620428, NP — 620427 and NP — 620429, or any other amino acid sequence at least 90%, or at least 95% homologous thereto, which retains BACE1 activity.
- APP or “amyloid precursor protein” refers to a substrate of BACE1 which may be metabolized into an ectodomain sAPP ⁇ fragment and a C-terminal fragment (CTF).
- CTF C-terminal fragment
- APP is an integral membrane protein expressed in many tissues and concentrated in, for example, the synapses of neurons.
- APP is a human APP, for example, Homo sapiens amyloid beta (A4) precursor protein (APP) encoded by an APP gene (e.g., GenBank Accession numbers: NM — 201414, NM — 201413, or NM — 000484), or any nucleic acid that encodes a human APP polypeptide.
- A4 Homo sapiens amyloid beta precursor protein
- APP can be encoded by any nucleic acid molecule exhibiting at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or up to 100% homology to any one of the APP genes (as determined by standard software, e.g. BLAST or FASTA), and any sequences which hybridize under stringent conditions to these sequences.
- standard software e.g. BLAST or FASTA
- APP may be characterized as comprising an amino acid sequence described by GenBank accession numbers: NP — 958817, NP — 958816, or NP — 000475, or any other amino acid sequence at least 90% or at least 95% homologous thereto and is cleavable by a human BACE1 protein.
- APP may be comprised in a fusion protein.
- the present invention provides for compounds that inhibit the activity of NFkB and/or BACE1.
- the invention provides for compounds of the following Formula
- R 1 , R 2 , R 3 , R 4 , R 5 are independently selected for each occurrence from the group consisting of hydrogen, halogen, alkyl, aryl, alkoxy, aryloxy, alkylthiol, arylthiol, CN, and NO 2 ; and
- R 10 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted alkenyl.
- R 1 , R 2 , R 3 , R 4 and R 5 are independently selected for each occurrence from the group consisting of hydrogen, methyl, Cl, OCH 3 , CF 3 , Br, and F.
- R 4 and R 5 are hydrogen
- R 1 , R 2 , and R 3 are independently hydrogen, halogen, alkyl, aryl, CN, alkoxy, aryloxy, NO 2 , alkylthio, and arylthio.
- R 10 is selected from the group consisting of phenyl, naphthyl, 2-Nitrophenyl, 3-Nitrophenyl, 4-Nitrophenyl, 4-Methyl-2-nitrophenyl, 2-Methyl-5-nitrophenyl, 2-Nitro-4-(trifluoromethyl)phenyl, 4-Methoxy-2-nitrophenyl, 2-Methyl-5-nitrophenyl, 4-Methyl-2-nitrophenyl, 4-Methylphenyl, 2-Aminophenyl, 2-Amino-4-methyl phenyl, Thiophen-2-yl, 5-Chlorothiophen-2-yl, 5-Bromothiophen-2-yl.
- compounds of Formula I may be synthesized according to the following scheme:
- R 1 , R 2 , R 3 , R 4 , R 5 and R 10 are defined as above for Formula I.
- compounds of Formula I may be synthesized by any means known in the art.
- the compound defined by Foiinula I is:
- the compound defined by Formula I is:
- the invention provides for compounds of the following Formula II:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are independently selected for each occurrence from the group consisting of hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted alkylthiol, substituted or unsubstituted arylthiol, CN, and NO 2 .
- R 4 and R 5 are hydrogen, and R 1 , R 2 , and R 3 are independently hydrogen, halogen, alkyl, aryl, CN, alkoxy, aryloxy, NO 2 , alkylthio, and arylthio.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are independently selected for each occurrence from the group consisting of hydrogen, methyl, Cl, OCH 3 , CF 3 and F.
- the compound defined by Formula II is:
- compounds of Formula II may be synthesized according to the following scheme:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are defined as above for Formula II.
- compounds of Formula II may be synthesized by any means known in the art.
- the compounds of Formula II may be synthesized according to the following scheme:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are defined as above for Formula II.
- the invention provides for compounds of the following Formula III:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are independently selected for each occurrence from the group consisting of hydrogen, halogen, alkyl, aryl, alkoxy, aryloxy, alkylthiol, arylthiol, CN, and NO 2 .
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently selected for each occurrence from the group consisting of hydrogen, methyl, Cl, OCH 3 , CF 3 , OH, and F.
- R 4 and R 5 are hydrogen
- R 1 , R 2 , and R 3 are independently hydrogen, halogen, alkyl, aryl, CN, alkoxy, aryloxy, NO 2 , alkylthio, and arylthio.
- compounds of Formula III may be synthesized according to the following scheme:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are defined as above for Formula III.
- compounds of Formula III may be synthesized by any means known in the art.
- the compounds of Formula III may be synthesized according to the following scheme:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are defined as above for Formula III.
- a compound of Formula I, II or III that inhibits NF ⁇ B activity may be used, in an effective amount, for the treatment of conditions including, but not limited to, cancer, tumorogenesis, and inflammatory conditions including, but not limited to, type I hypersensitivity, atopy, anaphylaxis, asthma, osteoarthritis, rheumatoid arthritis, septic arthritis, gout, juvenile idiopathic arthritis, still's disease, ankylosing spondylitis, inflammatory bowel disease, Crohn's disease or inflammation associated with vertebral disc herniation.
- a compound of Formula I, II or III that inhibits BACE 1 activity may be used, in an effective amount, in the treatment of neurodegenerative diseases, such as Alzheimer's disease.
- the present invention is directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation.
- the present invention provides for methods of treating diseases related to dysfunction of cell proliferation, the immune system and/or inflammation in a subject in need of such treatment by administration of a therapeutic formulation which comprises at least one compound of Formulas I-III.
- the formulation may be administered to a subject in need of such treatment in an amount effective to inhibit NFkB activity.
- the formulation may be administered systemically (e.g. by intravenous injection, oral administration, inhalation, subcutaneous, intramuscular, etc.), intraventricularly, intrathecally, or by any other means known in the art.
- the amount of the formulation to be administered may be determined using methods known in the art, for example, by performing dose response studies in one or more model system, followed by approved clinical testing in humans.
- the subject or patient has been diagnosed with, or has been identified as having an increased risk of developing a disease associated with dysfunction of cell proliferation, the immune system and/or inflammation.
- the present invention provides for methods of reducing in a subject, the risk of inflammatory damage comprising administering to the subject, an effective amount of a composition according to the invention.
- An effective amount may be a local concentration or, in a pharmaceutical composition, an amount that, when administered to a subject, results in a therapeutic benefit.
- an effective amount is an amount of at least one compound of Formulas I-III which reduces one or more clinical symptom of one or more of the aforementioned diseases.
- an effective amount is an amount of at least one compound of Formulas I-III that reduces the activity of NF ⁇ B, for example, by stabilizing I ⁇ B ⁇ or by inhibiting nuclear translocation of NF ⁇ B.
- the effective amount of at least one compound of Formulas I-III may be determined, for example, via an in vitro assay wherein the effective amount of a compound of Formulas I-III may be correlated with the compound's ability to stabilize I ⁇ B ⁇ .
- an assay may comprise a cell-based assay designed to identify compounds that stabilize I ⁇ B ⁇ , and thus reduce nuclear translocation of NFkB.
- the cell-based in vitro IkB ⁇ stabilization assay may utilize a dual reporter system, such as a luciferase reporter system in the cell line OCILy3, a model for primary tumors of the activated B-cell subtype (ABC) of diffuse large B-cell lymphoma (DLBCL) ( FIG. 5 ).
- the cell line used in the assay may exhibit a high NF ⁇ B activity level, for example, constitutive NFkB activity levels due to high levels of IKK ⁇ activity leading to elevated expression of NFkB targeted genes. IKK and proteasome activity may produce high levels of I ⁇ B ⁇ degradation, liberating NF ⁇ B heterodimers to translocate to the nucleus.
- modulators of IkB ⁇ stability may be identified by measuring changes in the level of expression of an IkB ⁇ reporter, for example, an exogenous IkB ⁇ -luciferase fusion reporter construct expressed by an NFkB-insensitive promoter.
- IkB ⁇ reporter expression may be measured in the presence or absence of a compound of the invention, wherein a greater increase in IkB ⁇ reporter expression by a cell contacted with the compound compared to the IkB ⁇ reporter expression in a cell not contacted with the compound is correlative with the therapeutic efficacy of the compound.
- a dual luciferase IkB ⁇ stabilization screen in OCI-Ly3 may be used for high throughput screening (HTS).
- HTS high throughput screening
- IkB ⁇ fused to a green light-emitting beetle luciferase and a red light-emitting beetle luciferase expressed in a native form can be used to monitor cell uniformity and non-specific effects.
- Fold-responsiveness may be further increased by having both reporters under the control of inducible promoters, for example, promoters regulated by doxycycline. Upon doxycycline induction of both luciferase reporters, compounds that increased green luminescence with minimal effects on the red luminescence signal may be identified as IkB ⁇ stabilizers, and thus an inhibitor of NF ⁇ B activity.
- the cell based in vitro IkB ⁇ stabilization assay may be the assay depicted in FIG. 5 a.
- an effective amount of a compound of Formulas I-III may be that amount which stabilizes IkB ⁇ , and a greater level of IkB ⁇ stabilization at a lower concentration when compared to a control level of IkB ⁇ stabilization, for example, as exhibited by a known IkB ⁇ stabilizing agent, such as MG-132 ( FIG. 6 ) is correlative with the therapeutic efficacy of the compound.
- the compound may stabilize IkB ⁇ with an efficacy of at least about 10-20%, at least about 20-50%, at least about 50-100%, at least about 100-200%, at least about 200-400%, or at least about 400-800% when compared to the IkB ⁇ stabilization achieved by a known IkB ⁇ stabilizing agent, such as MG-132.
- a known IkB ⁇ stabilizing agent such as MG-132.
- an effective amount of a compound of Formulas may be that amount which stabilizes IkB ⁇ with an EC 50 at a concentration ranging from about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, more preferably from about 50 ⁇ M to about 0.01 ⁇ M, and more preferably from about 20 ⁇ M to about 0.01 ⁇ M in the in vitro assay, wherein an EC 50 at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- the effective amount of at least one compound of Formulas I-III may be determined, for example, via an in vitro assay wherein the effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the nuclear translocation of NF ⁇ B.
- an assay may comprise a cell-based assay that utilizes an agent, for example, a cytokine such as TNF ⁇ , to stimulate nuclear translocation of endogenous NFkB.
- Stimulation by the agent may result in proteasome degradation of IkB ⁇ and subsequent translocation of NFkB from the cytoplasm to the nucleus, while in the absence of such a stimulatory agent, NFkB is sequestered in the cytoplasm due to its binding to IkB ⁇ .
- nuclear translocation of NFkB for example, the endogenous p65 RelA subunit
- nuclear translocation of NFkB may be detected and/or measured following stimulation with the agent through the use of, for example, but not limited to, fluorescent antibody detection and an automated imaging platform.
- Compounds of the invention may be contacted with cells of the in vitro assay, wherein a reduction in NFkB nuclear transport compared to a cell not contacted with the compound is indicative of the compound's ability to inhibit NF ⁇ B activity.
- a reduction in nuclear translocation of NF ⁇ B may be correlative with the compound's therapeutic efficacy.
- the cell based nuclear-translocation in vitro assay may be the assay depicted in FIG. 5 b.
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to inhibit NF ⁇ B nuclear-translocation, wherein a greater level of inhibition at a lower concentration when compared to a control level of inhibition, for example, as exhibited by a known NFiB nuclear-translocation inhibitor, such as BAY 11-7082 ( FIG. 6 ), is indicative of greater therapeutic efficacy of the compound.
- an effective amount of a compound of Formulas I-III may be that amount which inhibits NF ⁇ B nuclear-translocation with an efficacy of at least about 10-20%, at least about 20-50%, at least about 50-80%, or at least about 80-100% or more when compared to the NF ⁇ B nuclear-translocation inhibition achieved by a known inhibitor, such as BAY 11-7082.
- an effective amount of a compound of Formulas I-III may be that amount which inhibits NF ⁇ B nuclear-translocation by at least 50% when the compound is administered at a concentration ranging from about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, more preferably from about 50 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the in vitro assay, wherein inhibition of NF ⁇ B nuclear-translocation at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- the effective amount of at least one compound of Formulas I-III may be determined, for example, via an in vitro assay wherein the effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce expression of an NF ⁇ B-dependent reporter construct, for example, a ⁇ -lactamase reporter (NF ⁇ B-bla).
- an assay may comprise contacting a cell expressing the NF ⁇ B-dependent reporter construct, and monitoring the level of ⁇ -lactamase expression, wherein a decrease in expression compared to a cell not contacted with the compound indicates a reduction in NF ⁇ B activity.
- the reduction in expression of the NF ⁇ B-dependent reporter may be correlative with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be that amount which reduces expression of an NF ⁇ B-bla construct by at least 50% when the compound is administered at a concentration ranging from about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, more preferably from about 50 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the in vitro assay, wherein a reduction of NF ⁇ B-bla expression at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be an amount which achieves a local concentration at the therapeutic site of about 100 ⁇ M to about 0.01 ⁇ M, preferably from about 50 ⁇ M to about 0.01 ⁇ M, more preferably from about 20 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the in vitro assay.
- the present invention provides for methods of treating a neurodegenerative disease in a subject in need of such treatment comprising administering, to the subject, a therapeutically effective amount of at least one compound of Formulas I-III.
- neurodegenerative diseases include Alzheimer's disease, lewy body dementia, inclusion body myositis, and cerebral amyloid angiopathy.
- the present invention provides for methods of treating diseases related to metabolism of APP by BACE1 in a subject in need of such treatment by administration of a therapeutic formulation which comprises an effective amount of at least one compound of Formulas I-III.
- the formulation may be administered to a subject in need of such treatment in an amount effective to inhibit BACE1 activity and/or reduce the presence of sAPP ⁇ and/or A ⁇ .
- the formulation may be administered systemically (e.g. by intravenous injection, oral administration, inhalation, etc.), intraventricularly, intrathecally, or by any other means known in the art.
- the amount of the formulation to be administered may be determined using methods known in the art, for example, by performing dose response studies in one or more model system, followed by approved clinical testing in humans.
- the subject or patient has been diagnosed with, or has been identified as having an increased risk of developing a neurodegenerative disease, such as Alzheimer's Disease.
- the present invention provides for methods of reducing in a subject, the risk of neural damage comprising administering, to the subject, an effective amount of a composition according to the invention.
- An effective amount may be a local concentration or, in a pharmaceutical composition, an amount that, when administered to a subject, results in a therapeutic benefit.
- an effective amount is an amount of at least one compound of Formulas I-III which reduces one or more clinical symptom of one or more of the aforementioned diseases.
- an effective amount is an amount of at least one compound of Formulas I-III that reduces the production of sAPP ⁇ or A ⁇ generated by the metabolism of APP by BACE1.
- the effective amount of at least one compound of Formulas I-III may be determined via an in vitro assay, for example, as described in International Patent Application No. PCT/US2007015938 (Publication No. WO 2008008463), which is incorporated in its entirety herein for all purposes, wherein the effective amount may be correlated with the compound's ability to reduce the level of sAPP ⁇ .
- an assay may comprise a cell-based modified ELISA assay for measuring sAPP ⁇ , the secreted ectodomain of ⁇ -amyloid precursor protein (APP) following ⁇ -secretase (BACE1) cleavage.
- APP ⁇ -amyloid precursor protein
- BACE1 ⁇ -secretase
- the sAPP ⁇ ELISA assay may comprise cells, for example, SY5Y cells, transfected with a BACE1 reporter construct, such as a GFP-tagged BACE 1 (BACE-GFP), and a wild type APP reporter construct, such as a secreted alkaline phosphatase (SEAP)-tagged wild type APP (SEAP-APPwt).
- BACE 1 cleavage of the reporter-tagged APP e.g. SEAP-APPwt
- SEAP-APPwt secreted alkaline phosphatase
- SEAP-APPwt secreted alkaline phosphatase
- SEAP-APPwt secreted alkaline phosphatase
- SEAP-APPwt secreted alkaline phosphatase
- SEAP-APPwt secreted alkaline phosphatase
- SEAP-APPwt secreted alkaline phosphatase
- SEAP-APPwt secreted alkaline phosphata
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the level of sAPP ⁇ detected in the in vitro assay compared to a control cell culture that was not contacted with the candidate compound, wherein a reduction of sAPP ⁇ compared to the control cell culture correlates with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be that amount which reduces the level of sAPP ⁇ detected in the in vitro assay by at least 0.1, or by at least 0.5, or by at least 1, or by at least 1.5, or by at least 2, or by at least 2.5, or by at least 3, or by at least 3.5, or by at least 4, or by at least 4.5, or by at least 5, or by at least 5.5, or by at least 6 or more standard deviations above a control level of sAPP ⁇ reduction detected in the in vitro assay when the compound is tested at a concentration of about 2 ⁇ M, or about 10 ⁇ M, wherein such a reduction of sAPP ⁇ correlates with a compound's therapeutic efficacy.
- control level of sAPP ⁇ reduction may be the average sAPP ⁇ level in control cell cultures that are not contacted with the candidate compound. In other embodiments, the control level may be the average level of sAPP ⁇ reduction achieved by a series of compounds tested in the in vitro assay.
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce sAPP ⁇ levels by about 3 standard deviations greater than a control level of sAPP ⁇ reduction when the compound is administered at a concentration of 2 ⁇ M in the in vitro assay.
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPP ⁇ level by about 3 standard deviations greater than a control level of sAPP ⁇ reduction when the compound is administered at a concentration of 10 ⁇ M in the in vitro assay.
- an effective amount of a compound of Formulas may be that amount which reduces the level of sAPP ⁇ by at least 5%, by at least 10%, by at least 20%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 80%, by at least 90%, or by 100% when compared to sAPP ⁇ level in a control cell culture that was not contacted with the candidate compound, wherein such a reduction of sAPP ⁇ correlates with a compound's therapeutic efficacy.
- an effective amount of a compound of Formulas may be that amount which reduces the level of sAPP ⁇ by at least about 50% compared to a control cell culture that was not contacted with the candidate compound, wherein the compound is tested at a concentration ranging from about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the in vitro assay, wherein such a reduction of sAPP ⁇ at the above-described concentrations is correlative with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPP ⁇ level by about at least 50% when the compound is administered at a concentration of about 0.5 ⁇ M in the in vitro assay.
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPP ⁇ level by about at least 50% when the compound is administered at a concentration of about 1 ⁇ M in the in vitro assay.
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPP ⁇ level by about at least 50% when the compound is administered at a concentration of about 2 ⁇ M in the in vitro assay.
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPP ⁇ level by about at least 50% when the compound is administered at a concentration of less than 3 ⁇ M in the in vitro assay.
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPP ⁇ level by about at least 50% when the compound is administered at a concentration of about 5 ⁇ M in the in vitro assay.
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPP ⁇ level by about at least 50% when the compound is administered at a concentration of about 8 ⁇ M in the in vitro assay.
- an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPP ⁇ level by about at least 50% when the compound is administered at a concentration of about 10 ⁇ M in the in vitro assay.
- the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to inhibit the enzymatic activity of a BACE1 enzyme.
- the compound's BACE1 inhibitory effect may be assayed, for example, through use of a BACE1 FRET Assay kit (Invitrogen Corp., Carlsbad, Calif., U.S.A.), wherein the fluorescence resonance energy transfer (FRET)-based assay measures the cleavage by purified recombinant ⁇ -secretase of a peptide substrate corresponding to the BACE1 cleavage site of Swedish mutant APP.
- FRET fluorescence resonance energy transfer
- an effective amount of a compound of Formulas I-III may be that amount which inhibits BACE1 enzymatic activity by at least about 50% compared to a control cell culture that was not contacted with the candidate compound.
- the compound is tested at a concentration ranging from about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the in vitro assay, wherein such an inhibition of BACE1 enzymatic activity at the above-described concentrations is correlative with the compound's therapeutic efficacy.
- the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of A ⁇ 40 in an in vitro assay that measures the level of A ⁇ 40 produced in a cell line, for example, an SY5Y-BACEGFP-SEAPAPPwt cell line.
- the level of A ⁇ 40 expressed by the cell line may be measured through the use of an A ⁇ 40 Elisa kit (BioSource).
- the assay comprises incubating the A ⁇ 40 expressing cells with a compound of Formulas I-III, followed by assaying the concentration of A ⁇ 40 in the cell culture medium. In such an assay, a greater reduction of A ⁇ 40 concentration in the cell culture medium following incubation with a compound compared to a control cell culture not contacted with the compound is correlative with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be that amount which reduces the level of A ⁇ 40 in an in vitro assay by at least about 50% compared to a control cell culture that was not contacted with the candidate compound.
- the compound is tested at a concentration ranging from about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the in vitro assay, wherein such a reduction in the level of A ⁇ 40 at the above-described concentrations is correlative with the compound's therapeutic efficacy.
- the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of A ⁇ 40 in an in vitro assay that measures the level of A ⁇ 40 produced in a cell culture, for example, a culture of primary cortical neurons transduced with lentivirus carrying Swedish mutant APP (APPsw).
- the assay comprises incubating the A ⁇ 40 expressing cells with a compound of Formulas I-III, followed by assaying the concentration of A ⁇ 40 in the cell culture medium. In such an assay, a greater reduction of A ⁇ 40 concentration in the cell culture medium following incubation with a compound compared to a control cell culture not contacted with the compound is correlative with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be that amount which reduces A ⁇ 40 by about 1-10%, more preferably from about 10-20%, more preferably from about 20-30%, more preferably from about 30-40%, more preferably from about 40-50%, more preferably from about 50-60%, more preferably from about 60-70%, more preferably from about 70-80%, more preferably from about 80-90%, and more preferably from about 90-100%, compared to A ⁇ 40 levels in the cell culture medium of a control cell culture that was not incubated with the compound.
- the compound is incubated at a concentration of about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the in vitro assay, wherein a greater level of A ⁇ 40 reduction at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of sAPP ⁇ in an in vitro assay that measures the level of sAPP ⁇ produced in a cell culture, for example, primary cortical neurons transduced with lentivirus carrying Swedish mutant APP (APPsw).
- the assay comprises incubating the cells with a compound of Formulas I-III, followed by assaying the concentration of sAPP ⁇ in the cell culture medium. In such an assay, a greater reduction of sAPP ⁇ concentration in the cell culture medium following incubation with a compound compared to a control cell culture not contacted with the compound is correlative with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be that amount which reduces sAPP ⁇ by about 1-10%, more preferably from about 10-20%, more preferably from about 20-30%, more preferably from about 30-40%, more preferably from about 40-50%, more preferably from about 50-60%, more preferably from about 60-70%, more preferably from about 70-80%, more preferably from about 80-90%, and more preferably from about 90-100%, compared to sAPP ⁇ levels in the cell culture medium of a control cell culture that was not incubated with the compound.
- the compound is incubated at a concentration of about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the in vitro assay, wherein a greater level of sAPP ⁇ reduction at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be that amount which reduces A ⁇ 40 by about 50% in an in vitro assay compared to A ⁇ 40 levels in the cell culture medium of a control cell culture that was not incubated with the compound.
- the compound is incubated at a concentration of about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to 0.01 ⁇ M in the in vitro assay, wherein a reduction of A ⁇ 40 at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of A ⁇ 40 in an in vitro assay that measures the level of A ⁇ 40 produced in a cell culture, for example, cultured primary cortical neurons prepared from Tg2576 mice (i.e. mice carrying human APPsw transgene under the control of the PrP promoter).
- the assay comprises incubating the A ⁇ 40 expressing cells with a compound of Formulas I-III, followed by assaying the concentration of A ⁇ 40 in the cell culture medium. In such an assay, a greater reduction of A ⁇ 40 concentration in the cell culture medium following incubation with a compound compared to a control cell culture not contacted with the compound is correlative with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be that amount which reduces A ⁇ 40 by about 1-10%, more preferably from about 10-20%, more preferably from about 20-30%, more preferably from about 30-40%, more preferably from about 40-50%, more preferably from about 50-60%, more preferably from about 60-70%, more preferably from about 70-80%, more preferably from about 80-90%, and more preferably from about 90-100%, compared to A ⁇ 40 levels in the cell culture medium of a control cell culture that was not incubated with the compound.
- the compound is incubated at a concentration of about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the in vitro assay, wherein a greater level of A ⁇ 40 reduction at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of A ⁇ 40 and/or sAPP ⁇ in an ex vivo assay that measures the level of A ⁇ 40 and/or sAPP ⁇ produced in cells, for example, organotypic brain slices from Tg2576 mice (i.e. mice carrying human APPsw transgene under the control of the PrP promoter).
- the assay comprises incubating the brain slices with a compound of Formulas followed by assaying the concentration of A ⁇ 40 and/or sAPP ⁇ in the brain slices. In such an assay, a greater reduction of A ⁇ 40 and/or sAPP ⁇ concentration in the brain slices following incubation with a compound compared to a control brain slice not contacted with the compound is correlative with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be that amount which reduces A ⁇ 40 and/or sAPP ⁇ by about 1-10%, more preferably from about 10-20%, more preferably from about 20-30%, more preferably from about 30-40%, more preferably from about 40-50%, more preferably from about 50-60%, more preferably from about 60-70%, more preferably from about 70-80%, more preferably from about 80-90%, and more preferably from about 90-100%, compared to A ⁇ 40 and/or sAPP ⁇ levels in control brain slices that were not incubated with the compound.
- the compound is incubated at a concentration of about 200 ⁇ M to about 0.01 ⁇ M, preferably from about 100 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the ex vivo assay, wherein a greater level of A ⁇ 40 and/or sAPP ⁇ reduction at a lower concentration in the ex vivo assay is correlative with the compound's therapeutic efficacy.
- the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of A ⁇ 40 and/or sAPP ⁇ in an in vivo assay that measures the level of A ⁇ 40 and/or sAPP ⁇ produced in a test subject, for example, a Tg2576 mouse (i.e. mice carrying human APPsw transgene under the control of the PrP promoter).
- the assay comprises administering at least one compound of Formulas I-Ill to the test subject, for example, via interstitial fluid (ISF) compound administration, intraperitoneal (IP) compound injection, or through the use of a microdialysis apparatus for infusion of the compound at multiple concentrations (for example, in the hippocampus of the test subject), followed by assaying the concentration of A ⁇ 40 and/or sAPP ⁇ in the test subject.
- ISF interstitial fluid
- IP intraperitoneal
- a microdialysis apparatus for infusion of the compound at multiple concentrations (for example, in the hippocampus of the test subject)
- a microdialysis apparatus for infusion of the compound at multiple concentrations (for example, in the hippocampus of the test subject)
- a microdialysis apparatus for infusion of the compound at multiple concentrations (for example, in the hippocampus of the test subject)
- a microdialysis apparatus for infusion of the compound at multiple concentrations (for example, in the
- an effective amount of a compound of Formulas I-III may be that amount which reduces A ⁇ 40 and/or sAPP ⁇ by about 1-10%, more preferably from about 10-20%, more preferably from about 20-30%, more preferably from about 30-40%, more preferably from about 40-50%, more preferably from about 50-60%, more preferably from about 60-70%, more preferably from about 70-80%, more preferably from about 80-90%, and more preferably from about 90-100%, compared to A ⁇ 40 and/or sAPP ⁇ levels in brain homogenates of subjects that were not administered the compound.
- the compound is administered at a concentration of about 0.5 mg/kg to about 20 mg/kg, preferably from about 1 mg/kg to about 20 mg/kg, more preferably from about 3 mg/kg to about 20 mg/kg, more preferably from about 5 mg/kg to about 20 mg/kg, more preferably from about 10 mg/kg to about 20 mg/kg in the in vivo assay, wherein a greater level of A ⁇ 40 and/or sAPP ⁇ reduction at a lower concentration in the in vivo assay is correlative with the compound's therapeutic efficacy.
- an effective amount of a compound of Formulas I-III may be an amount which achieves a local concentration at the therapeutic site of about 100 ⁇ M to about 0.01 ⁇ M, preferably from about 50 ⁇ M to about 0.01 ⁇ M, more preferably from about 20 ⁇ M to about 0.01 ⁇ M, and more preferably from about 10 ⁇ M to about 0.01 ⁇ M in the in vitro assay.
- the component or components of a pharmaceutical composition of the invention may be administered to a subject by means including but not limited to intravenous, intra-arterial, intramuscular, intradermal, transdermal, subcutaneous, oral, intraperitoneal, intraventricular, and intrathecal administration.
- the therapeutic compound can be delivered in a controlled or sustained release system.
- a compound or composition may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration.
- a pump may be used (see Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201; Buchwald et al., 1980, Surgery 88:507; Saudek et al., 1989, N. Engl. J. Med. 321:574).
- polymeric materials can be used (see Langer and Wise eds., 1974, Medical Applications of Controlled Release, CRC Press: Boca Raton, Fla.; Smolen and Ball eds., 1984, Controlled Drug Bioavailability, Drug Product Design and Performance, Wiley, N.Y.; Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem., 23:61; Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neural., 25:351; Howard et al., 9189, J. Neurosurg. 71:105).
- a controlled release system can be placed in proximity of the therapeutic target, i.e., the heart or a blood vessel, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical Applications of Controlled Release, supra, Vol. 2, pp. 115-138).
- Other controlled release systems known in the art may also be used.
- compositions of the invention may be formulated as pharmaceutical compositions by admixture with a pharmaceutically acceptable carrier or excipient.
- the pharmaceutical composition may comprise an effective amount of at least one compound of Formulas I-III and a physiologically acceptable diluent or carrier.
- the pharmaceutical composition may further comprise a second drug, for example, but not by way of limitation, an anti-cancer drug, an anti-inflammatory drug, for example, but not limited to, a steroid compound and/or a non-steroidal anti-inflammatory drug, or compound for the treatment of Alzheimer's disease, such as an acetylcholinesterase inhibitor or an NMDA glutamate receptor antagonist (e.g. memantine).
- a second drug for example, but not by way of limitation, an anti-cancer drug, an anti-inflammatory drug, for example, but not limited to, a steroid compound and/or a non-steroidal anti-inflammatory drug, or compound for the treatment of Alzheimer's disease, such as an acetylcholinesterase inhibitor or an NMDA glutamate receptor antagonist (e.g. memantine).
- phrases “pharmaceutically acceptable” indicates that a substance is physiologically tolerable when administered to a subject.
- pharmaceutically acceptable means approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered.
- Such pharmaceutical carriers can be sterile liquids, such as water and oils, or, for solid dosage forms, may be standard tabletting excipients.
- Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions.
- Suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin, 18th Edition, or other editions.
- the therapeutic compound can be delivered in a vesicle, in particular a liposome (see Langer, 1990, Science 249:1527-1533; Treat et al., 1989, in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler eds., Liss: New York, pp. 353-365; Lopez-Berestein, ibid., pp. 317-327; see generally Lopez-Berestein, ibid.).
- a liposome see Langer, 1990, Science 249:1527-1533; Treat et al., 1989, in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler eds., Liss: New York, pp. 353-365; Lopez-Berestein, ibid., pp. 317-327; see generally Lopez-Berestein, ibid.).
- the compounds of Formulas I and II consist of N-(quinolin-8-yl)benzensulfonamides, and the compounds of Formula III consist of a structurally constrained cyclic sulfonamide with the sultam bridging quinolinyl and phenyl moieties.
- This particular scaffold lacks a general synthetic method. Described here is an efficient synthesis of this class of compounds that allows a diverse substitution pattern.
- the synthetic strategy was to generate N-8-quinolinyl benzenesulfonamides, and then construct the sultam skeleton through cyclization of the easily accessible N-8-quinolinyl benzenesulfonamides.
- Diazotization-induced cyclization was employed to synthesize the target compound ( FIG. 2 ).
- Sulfonamide 8 was prepared from 2-nitrobezenesufonyl chloride and 8-aminoquinoline 2 in pyridine. The nitro group was reduced with SnCl 2 to provide amine 9 and subsequent diazotization afforded triazine 10.
- a procedure employing Cu (0) and NaOH (Ullman et al., 1911, Ber. Dtsch. Chem. Ges.
- a second synthetic method involves a one-pot synthesis of N-8-quinolinyl benzenesultams from N-8-quinolinyl-2-aminobezenesulfonamides.
- 2-aminobenzenesulfonamide 9a prepared from 6-methoxy-2-methylquinolin-8-amine 2a (Qiu et al., 2007, Inorg. Chim. Acta. 360:431), was dissolved in HOAc and treated with 1.5 equiv of t-BuONO at 10° C. The reaction was allowed to warm to room temperature over 10 minutes and afforded sultam 1a in (78% yield) without isolation of the triazine intermediate.
- N-8-quinolinyl-2-aminobezenesulfonamides (9a-p) were prepared and subsequently cyclized in similar one-pot reactions to give sultams (1a-p) ( FIG. 4 ). In each case, the product was isolated without intermediate purification ( FIG. 4 ).
- Aminobezenesulfonamides (9b-h and 9l-p) were synthesized in a similar manner described in FIG. 3A .
- Intermediates 9i-k were prepared from aniline 11 as outlined in FIG. 3B : Sulfonamidation of aniline 11 with 2-nitrobezenesufonyl chloride provided sulfonamide 12. Skraup reaction under modified conditions (Matsugi et al., 2000, Tetrahedron Lett. 41:8523) followed by reduction of nitro group provided the N-quinolinyl sulfonamides (9i-k).
- Small molecule regulation of signaling cascades associated with NFkB may provide novel approaches to alleviate numerous disease states, (D'Acquisto, et al., 2006 Curr. Opin. Pharmacol. 6:387; Gilmore, et al., 2006, Oncogene 25:6887).
- Several high-throughput campaigns in search of novel inhibitors of the NFkB signal transduction pathway have been undertaken. Two of these include a cell-based assay designed to identify IkB ⁇ stabilization, and a cell-based assay designed to identify inhibitors of TNF ⁇ -induced translocation of NFkB.
- a N-(quinolin-8-yl)benzenesulfonamide core scaffold was identified in both screens.
- the first assay was performed using a dual luciferase reporter system in the cell line OCILy3, an excellent model for primary tumors of the activated B-cell subtype (ABC) of diffuse large B-cell lymphoma (DLBCL) ( Figure SA; PubChem AID: 445) (Davis, et al., 2007, Drug Dev. Technol. 5:85; Davis, et al., 2001, J. Exp. Med. 184:1861; Okamoto, et al., 2007, Curr. Pharm. Des.
- the dual luciferase IkB ⁇ stabilization screen in OCI-Ly3 employed was designed to be suitable for HTS, by using IkB ⁇ fused to a green light-emitting beetle luciferase, with a red light-emitting beetle luciferase expressed in a native form to monitor cell uniformity and non-specific effects.
- Fold-responsiveness was further increased by having both reporters under the control of inducible promoters regulated by doxycycline.
- the second assay was a high-content screen performed in human umbilical vein endothelial cells (HUVEC) using TNF ⁇ to stimulate nuclear translocation of endogenous NFkB (Figure SB; PubChem AID: 438).
- NFkB is sequestered in the cytoplasm due to its binding to IkB ⁇ , which blocks exposure of a nuclear localization sequence.
- Activation by cytokines such as TNF ⁇ results in proteasome degradation of IkB ⁇ and subsequent translocation of NFkB from the cytoplasm to the nucleus.
- NFkB inhibitors in this assay were detected as compounds that interfered with p65 translocation to the nucleus.
- the above-described assays were validated using known inhibitors of the NFkB pathway ( FIG. 6 ).
- the proteasome inhibitor MG-132 (1) 16 served as a positive control for the IkB ⁇ stabilization assay.
- the translocation assay used BAY 11-7082 (2), an agent that inhibits the TNF ⁇ -induced phosphorylation of IkB ⁇ . (Kamthong, 2001, Biochem 356:525; Izban et al., 2000, Hum. Pathol. 31:1482; Pierce et al., 1997, J. Biol. Chem. 272:21096).
- a substituted 2-(thiophen-2-yl)quinazoline 3 which acts as an inhibitor of NFkB and AP1 mediated transcriptional activation (Palanki et al., 2003, Bioorg. Med. Chem. Lett. 13:4077) was used as a positive control in a secondary assay that used TNF ⁇ to stimulate NFkB-dependent expression of a ⁇ -lactamase reporter (NFkB-bla in FIG. 7 ). This compound also served as a negative control for the dual luciferase IkB ⁇ stabilization assay.
- N-(quinolin-8-yl)benzenesulfonamide (4) and the related C7-locked N-(quinolin-8-yl)benzenesulfonamide (5) were identified as two common structures in both screens ( FIG. 6 ).
- a reporter assay obtained from Invitrogen where induction of ⁇ -lactamase occurred in an NFkB-dependent manner was also performed on the active compounds. These data confirmed the ability of these compounds to inhibit the NFkB pathway, and the compounds were then advanced for further study ( FIG. 7 ).
- Analogues of (4) and (5) were analyzed within both screens. Results for analogues of (4) are shown in FIG. 7A , while the results for derivatives of (5) are shown in FIG. 7C . In general, there was agreement in the relative potencies of analogues tested in both screening assays, as well as the NFkB ⁇ -lactamase reporter assay (although exceptions do exist).
- This assay has been described in International Application PCT/US2007015938 (Published as International Publication No. WO 08/008463), which is herein incorporated in its entirety for all purposes.
- BACE1-mediated cleavage of APP is a key and necessary event in the generation of neurotoxic ⁇ -amyloid (A ⁇ ), a widely accepted contributor to the development of Alzheimer's disease (AD).
- a ⁇ neurotoxic ⁇ -amyloid
- AD Alzheimer's disease
- the SY5Y-BACEGFP-SEAPAPPwt cell based assay was developed to discover novel small molecule modulators of BACE1 activity.
- SY5Y cells were stably transfected with GFP-tagged BACE1 (BACE-GFP) and secreted alkaline phosphatase (SEAP)-tagged wildtype APP (SEAP-APPwt).
- BACE1 cleavage of SEAP-APPwt results in secretion into the media of SEAP-tagged sAPP ⁇ , which is collected and specifically captured using an sAPP ⁇ cleavage site-specific antibody (s ⁇ wt).
- s ⁇ wt an sAPP ⁇ cleavage site-specific antibody
- the fluorescent alkaline phosphatase substrate 4-methylumbelliferyl phosphate (4-MUP) is used to detect the captured SEAP-sAPP ⁇ ( FIG. 8 ).
- N-(quinolin-8-yl)benzenesulfonamides ( FIG. 2 ) were recently reported as agents capable of down-regulating NF- ⁇ B activity (Xie et al., 2008).
- NF- ⁇ B is a ubiquitous transcription factor that is thought to play a role in many cellular processes, including immune and inflammatory responses, developmental processes, cellular growth, and apoptosis.
- Dysregulation of NF- ⁇ B signaling has been associated with many disease states, including asthma, arthritis, cancer, inflammatory conditions, neurodegenerative diseases, and heart disease (reviewed in Kumar et al., 2004).
- NF- ⁇ B inhibitors have also been reported to inhibit Ap production (Paris et al., 2007).
- N-(quinolin-8-yl)benzenesulfonamides bear structural similarity to clioquinol and its second-generation compound PBT2. Both clioquinol and PBT2 are believed to be strong metal ion chelators that may interfere with oligomerization and aggregation of AP and promote its clearance (Ritchie et al., 2003). PBT2, developed by Prana Biotechnology, is currently in Phase II clinical trial for the treatment of AD. Thus, a small library of N-(quinolin-8-yl)benzenesulfonamides and related compounds was screened for agents that reduce BACE1-mediated cleavage of APP.
- each compound (10 mM stock in DMSO) was diluted 1:25 in DMSO and loaded onto 96-well plates to generate a 400 ⁇ M stock plate. 1 ⁇ l of each compound was then diluted 1:200 with cell culture media (0.5% DMSO concentration) in two separate 96-well plates for a final screening concentration of 2 ⁇ M. 150 ⁇ l of media containing compound was then transferred onto SY5Y-BACEGFP-SEAPAPPwt cells in 96-well format, and the BACE1 assay was performed as described previously. The primary screen was conducted in duplicate. A parallel screen was conducted at 10 ⁇ M concentration, also in duplicate. This data is not shown.
- Percent inhibition of the fluorescence signal was calculated as 100 ⁇ [DMSO control compound]/DMSO control The majority of data points were clustered between ⁇ 25% and 25% inhibition of sAPP ⁇ fluorescence signal ( FIG. 9A ). The Z′ factors for all 4 96-well plates used in the primary screen were above 0.7 (data not shown). The threshold for hit selection was set at 3 standard deviations, or 59.76% inhibition, yielding 6 small molecule hits and a hit rate of 3.41% ( FIG. 9B ).
- a cell-based BACE1 assay was used to screen N-(quinolin-8-yl)benzene-sulfonamides and related compounds, a class of NF- ⁇ B inhibitors. Because of their potency, availability, and the reported connection between NF- ⁇ B inhibition and AP generation, structural analogs of N-(quinolin-8-yl)benzenesulfonamides were also selected for investigation in structure-activity relationship studies. Primary and secondary screening using the cell-based BACE1 assay thus yielded chemotypes for SAR studies and further characterization in more physiological systems.
- Targeted screening of N-(quinolin-8-yl)benzenesulfonamides and related compounds revealed several full and partial hits capable of reducing the fluorescent signal from the cell-based BACE1 assay. Based on the chemical structures of the 176 compounds as well as the full and partial hits from the targeted screen, the structural elements that were critical for activity were identified. All full and partial hits contained the sulfonamide of quinoline motif either in open or cyclized varieties, as shown in FIG. 10 . Substituting naphthalene for quinoline or removal of the sulfonamide substituent resulted in loss of activity.
- Lenti-APPsw cultured mouse cortical neurons (postnatal day 0) infected with recombinant lentivirus carrying human APPsw (Lenti-APPsw; FIG. 11 ); and cultured cortical neurons prepared from Tg2576 mice (carrying human APPsw transgene under the control of the PrP promoter). Lenti-APPsw infected cortical neurons can be prepared in a relatively large scale, but suffer from variability in lentiviral infection efficiency, resulting in variable levels of APP expression.
- cortical neurons derived from Tg2576 provide constant APP expression.
- neuronal yield is generally much lower, since only half the pups will contain the transgene when heterozygote crossbreeds were conducted. Therefore, Initial characterization experiments were performed using cortical neurons infected with Lenti-APPsw. Compounds exhibiting inhibitory activity on sAPP ⁇ and/or A ⁇ would then be re-evaluated in Tg2576 mice-derived neurons.
- Ex vivo and in vivo assays will be used to characterize certain hit(s).
- Ex vivo systems such as organotypic brain slices, offer an alternative to in vivo assays, and can also be used to test a large number of compounds. Further more, at least with regard to the A ⁇ release phenotype, brain slice data have been shown to correlate well with the results obtained in vivo (reviewed in Noraberg et al., 2005). Brain slices from p7 Tg2576 pups are used herein for compound characterization.
- interstitial fluid (ISF) compound administration and A ⁇ measurement, as well as intraperitoneal (IP) compound injection, both utilizing Tg2576 mice, will be used to characterize compounds.
- Positioning of a guide cannula to the mouse hippocampus allows for insertion of a microdialysis apparatus, which can be used to infuse compounds at multiple concentrations sequentially in the awake mouse.
- a ⁇ measurements can be performed using the same apparatus, yielding rapid dose-response determinations (Cirrito et al., 2003).
- This method allows for rapid assessment of compound effect on AP on a dynamic time scale. More conventionally, compounds can also be administered via IP injection. For these experiments, 12-month old Tg2576 mice will be used.
- CU-264 does not Reduce A ⁇ 40 in Lenti-APPsw Infected Primary Cortical Neurons
- Lenti-APPsw infected primary cortical neurons were used for the initial round of physiological experiments.
- Primary cortical neurons were harvested from wild-type P0 pups using established protocols. The majority of cells from the resulting culture exhibit neuronal morphology on light microscopy and express neuronal ⁇ -tubulin as visualized by immunocytochemistry using the TUJ1 antibody (Covance, FIG. 12 ).
- the Lenti-APPsw vector was co-transfected into HEK293 T cells with ViraPower packaging mix (Invitrogen) to generate the lentivirus.
- Lentiviral-mediated transduction of APPsw in primary neurons was performed by adding neuron primary culture media containing the lentiviral particles to wild-type DIV-14 primary neurons ( FIG. 11 ). After 24 hours, neurons were incubated with media for 72 hours prior to collecting for A ⁇ 40 measurement. Two batches of virus (LV-1 and LV-2) were tested, showing that there is batch-to-batch variation in the viral titer.
- CU-264 was tested at 10 and 2 ⁇ M concentrations to examine the sAPP ⁇ - and A ⁇ -lowering activity of the compound.
- the protocol was modified slightly to allow for 24-hour compound treatment.
- DIV-14 wild-type primary neurons FIG. 12
- primary culture media containing lentiviral particles After infection, fresh media was mixed in a 1:1 ratio with conditioned media collected prior to lentiviral infection, and applied to the cells for 48 hours to allow for APP expression.
- media containing compound was applied for 24-hour treatment.
- CU-264 which exhibited sub-micromolar potency for sAPP ⁇ reduction in SY5Y-BACEGFP-SEAPAPPwt cells, did not reduce A ⁇ 40 in primary neurons ( FIG. 13A ). In contrast, CU-264 was observed to increase AP at 10 ⁇ M.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to compounds with activity as BACE1 and NFκB modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such compounds or pharmaceutical compositions containing such candidate compounds.
Description
- The present application is a continuation of International Application No. PCT/US2009043011, filed May 6, 2009 and published in English as WO2010051064 on May 6, 2010, which claims the priority benefits of U.S. Provisional Application No. 61/109,891, filed Oct. 30, 2008; U.S. Provisional Application No. 61/143,404, filed Jan. 8, 2009; and U.S. Provisional Application No. 61/143,532, filed Jan. 9, 2009, all four of which are hereby incorporated by reference in their entireties.
- This invention was made with government support under grants P50 AG08702, and 5RO1 AT001643 awarded by the National Institutes of Health, the Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research and the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. The government has certain rights in the invention.
- The present invention relates to compounds with activity as NFκB inhibitors. The present invention also relates to methods for treating, preventing, and/or ameliorating diseases related to dysfunction of cell proliferation, the immune system, inflammation and/or neurodegeneration using such compounds or pharmaceutical compositions comprising such compounds.
- Nuclear factor-κ B (NFκB) signaling is an essential signal transduction pathway involved in inflammatory responses, oncogenesis, viral infection, the regulation of cell proliferation and apoptosis and, in particularly in the case of B and T lymphocytes, in antigenic stimulation (Ghosh, 1998, Annu. Rev. Immunol., 16, 225-260; Karin, 1999, J. Biol. Chem., 274, 27339-27342; Israel, 2000, Trends Cell. Biol., 10, 129-133; Santoro, 2003, EMBO J., 22, 2552-2560). In mammalian cells, there are five NFκB family members that dimerize: RelA, RelB, c-Rel,
NFκB 2/p100/p52 andNFκB 1/p105/p50. NFκB, whose predominant form is a heterodimeric transcription factor composed of p50 and RelA subunits, remains sequestered in the cytoplasm through association with members of an inhibitory family of proteins known as IκB. Upon stimulation by the cytokines TNF-α and interleukin-1, endotoxin (LPS), microbial and viral infections, pro-inflammatory signals converge on the canonical IkB kinase complex (IKK), a protein complex that is composed of two kinase subunits, IKKα/IKK-1 and IKKβ/IKK-2 and a structural/regulatory subunit NEMO/IKK-γ. Once activated IKK complex phosphorylates IkB proteins, triggering their ubiquitination and subsequent degradation by the proteasome. Free NFκB can then move into nucleus to initiate or up-regulate gene expression. - Although IKKα and IKKβ exhibit striking structural similarity (52%), genetic studies have shown that they are involved in two pathways for the activation of NFκB (Pomerantz, 2002, Molecular Cell 2002 10: 693-695). IKKβ has been identified as the pro-inflammatory kinase responsible of activation of classical NFκB complexes, whereas IKKα in association with NFκB inducing kinase (NIK) plays an essential role in the non-canonical NFκB signaling pathway (Senftleben, 2001, 293: 1495-1499).
- NFκB plays an essential role in the development and progression of cancer, including breast cancer. Animal studies suggest the presence of constitutively active NFκB at an early stage during neoplastic transformation of mammary cells (Clarkson et al., 2000, J Bio Chem. 275(17):12737-42). NFκB inhibits apoptosis in mouse mammary epithelia (Soy ak et al., 1999, Cell Growth Differ. 10(8):537-44) and selective activation of NFκB subunits have been found in human breast cancer cell lines and patient samples (Sovak et at, 1997, J Clin Invest. 100(12):2952-60; Cogswell et al., 2000, Oncogene 19(9):1123-31). An inverse correlation between the levels of NFκB activation and estrogen receptor expression has been reported (Nakshatri et al., 1997, Mol Cell Biol. 17(7):3629-39) and inhibition of NFκB in breast cancer cells induces spontaneous apoptosis (Sovak et al., 1999, Cell Growth Differ. 10(8):537-44; Cogswell et al., 2000, Oncogene 19(9):1123-31). Paclitaxel-induced sensitivity of breast cancer cell lines was enhanced by an NFκB inhibitor, parthenolide (Patel et al., 2000, Oncogene 19(36):4159-69; Newton et al., 1999, J Bio Chem. 274(26):18827-35). The Mullerian inhibiting substance was also found to inhibit breast cancer growth through NFκB mediated pathway (Segev et al., 2000, J Bio Chem. 275(37):28371-9). Furthermore, the transactivation function of NFκB is negatively regulated by IKI411 in breast cancer cell lines (Newton et al., 1999, J Bio Chem. 274(26):18827-35). Lastly, overexpression of HER2neu can activate NFκB through the activation of Akt pathway and block apoptosis (Zhou et al., 2000, J Bio Chem. 275(10:8027-31). All these reports together suggest that NFκB plays an important role in cancer generally and in breast cancer specifically.
- In light of the foregoing, inhibition of NFκB activation represents a target for development of new anti-inflammatory and anti-cancer drugs (Poulaki, 2002, Am J Pathol. 161: 2229-2240). Among many protein actors in NFκB signaling pathway, IKK complex represents one of the most promising molecular targets for discoveries of new specific NFκB inhibitors. To minimize the potential toxicity effects in vivo, therapeutic success will greatly depend on the abilities of the NFκB inhibitors to block activating signals without modifying the basal level of NFκB activity. For example, May et al. described a cell-permeable peptidic inhibitor that specifically blocks the pro-inflammatory NFκB activation by disrupting the constitutive NEMO interaction with IKK kinases (May, 2000, Science 289, 1550-1554; May, 2002, J. Biol. Chem. 277, 45992-46000). Accordingly, it would be desirable to identify additional small molecules that can reduce NFκB activity by selectively inhibiting NFκB and/or components of the NFκB signaling pathway.
- The present invention relates to compounds which inhibit NFκB activity. The compounds of the invention may be used to inhibit NFκB activity in a subject, or in a cell in culture.
- The present invention also provides a method for the treatment of a dysfunction of cell proliferation, the immune system and/or inflammation in an individual, wherein the dysfunction is associated with NFκB activity, by administering to an individual in need of such treatment a pharmaceutical composition comprising at least one compound of Formulas I-III in an amount effective to treat the dysfunction.
- In particular non-limiting embodiments, the present invention relates to a compound of Formula I:
- and to salts, esters and prodrugs of the compounds of Formula I. Additionally, the present invention describes methods of synthesizing and using compounds of Formula I.
- In other non-limiting embodiments, the present invention relates to a compound of Formula II:
- and to salts, esters and prodrugs of the compounds of Formula II. Additionally, the present invention describes methods of synthesizing and using compounds of Formula II.
- In further non-limiting embodiments, the present invention relates to a compound of Formula III:
- and to salts, esters and prodrugs of the compounds of Formula III. Additionally, the present invention describes methods of synthesizing and using compounds of Formula III.
- The present invention also provides a method of inhibiting the activity of NFκB, by contacting the NFκB, an NFκB associated protein, or a cell expressing NFκB, with at least one compound of Formulas I-III (meaning Formula I, Formula II, or Formula III) in an amount effective to inhibit the activity of NFκB.
- In one non-limiting embodiment, the NFκB is expressed by a cell, for example, a mammalian cell, and the cell is contacted with an effective amount of at least one compound of Formulas I-III.
- In another embodiment, the NFκB, or cell expressing NFκB, is contacted with an effective amount of at least one compound of Formulas I-III in vitro.
- In other non-limiting embodiments, the pharmaceutical composition may optionally be used in conjunction with one or more additional compound for the treatment of a dysfunction of cell proliferation, the immune system and/or inflammation.
- It has further been discovered that some of these compounds inhibit BACE1, an enzyme that participates in the production of Aβ. As Aβ has been linked to neurodegeneration and to Alzheimer's Disease in particular, such compounds may be used in the treatment of neurodegenerative conditions and in particular in Alzheimer's Disease and related conditions.
-
FIG. 1A-B depicts general structure of N-(quinolin-8-yl)benzenesulfonamides. A) Open chain and B) cyclized structures. -
FIG. 2 depicts a method for synthesizing a particular compound of Formula II (the particular compound identified as compound 9) and a particular compound of formula III (the particular compound identified as compound I). -
FIG. 3A-B depicts (A) a one-pot synthesis reactionmechanism synthesizing compound 9a of Formula II and compound I a of Formula III. (B) depicts the synthesis of particular compounds of Formula II (the particular compounds identified as 9i, 9j, and 9k). -
FIG. 4 depicts a one-pot synthesis reaction mechanism for converting particular compounds of Formula II into particular compounds of Formula III. The particular R groups of the starting compounds (9a-p) and the corresponding synthesized compounds (1a-p) are identical in each synthesis, and are illustrated in the table along with the individual yields of compounds 1a-p. -
FIG. 5A-B depicts (A) The two-color dual luciferase based assay. IκBα is fused to a luciferase emitting greenlight (CBG68), while a red light-emitting luciferase (CBR) is present in its native state. Both luciferases are regulated by binding of the tet repressor to the tet operator (TO) binding site (TO), allowing simultaneous induction of the luciferases by the CMV promoter upon addition of doxycycline and test compounds. The CBR protein serves to normalize for non-specific effects, while the levels of the IκBα-CBG68 protein increase uniquely with inhibition of the NFκB pathway leading to IκBα degradation. (B) The nuclear translocation assay. TNFα stimulation results in nuclear translocation of NFκB, which is detected by immunofluorescence using an anti-p65 antibody and a secondary antibody labeled with an Alexa 647 fluorophore (A647). -
FIG. 6 depicts several compounds identified by the NFkB inhibition screens illustrated inFIG. 4 , including Structures of MG-132 (1), BAY11-7082 (2), a quinazoline based inhibitor of AP1 and NFκB mediated transcription (3), N-(quinolin-8-yl)benzenesulfonamide; PubChem CID: 161167 (4), and C7-locked N-(quinolin-8-yebenzenesulfonamide (5); PubChem CID: 659101. -
FIG. 7A-D depicts the NFκB inhibitory effect achieved by exemplary compounds of Formulas I and III in three cell-based NFκB activity assays.FIGS. 7A and C show the inhibitory effect of the compounds as measured by an IκBα stabilization assay, NFκB nuclear-translocation assay, and NFκB-bla expression assay. In the IκBα stabilization assay, a higher efficacy of IκBα stabilization compared to stabilization achieved by MG-132 (an IκBα stabilizing agent) indicates greater NFκB inhibition. IκBα stabilization was measured as an increase in luminescence of a green luciferase IκBα construct. Stabilization at a lower EC50 concentration further indicates more potent NFκB inhibition. A red luciferase under the same regulatory control as the IκBα construct was used as a control to monitor cell uniformity and non-specific effects. Compounds that stabilized IκBα were those that increased green luminescence with minimal effects on red luminescence. (aEC50 values from the IκBα stabilization assay shown for the green luminescence reporter along with the % efficacy. bEC50 values from the ratio of the green and red luminescent values for the IκBα stabilization. Data are averages from two to three experiments where each experiment consisted of concentration-titration for each compound performed in duplicate and fitting concentration-response curves to the response after bioassay. NA, not applicable; the compound only showed a strong inhibitory response in the original qHTS (IC50=2.5 μM, 95% inhibition) in the non-specific (red luminescence) dataset.) - In the nuclear-translocation and NFκB-bla expression assays, inhibition of NFκB nuclear-translocation or NFκB-bla expression at a lower IC50 concentration indicates a stronger NFκB inhibitory effect. Cytotoxicity for each compound is also shown. (cIC50 values are derived from curve-fitting to data from a single experiment performed in triplicate. ND, not determined. All compounds showed >90% efficacy in the translocation assay except compounds 15 (78%) and 27 (75%). The cytotoxicity assay was performed in OCI-Ly3 cells using a 4 h endpoint.)
FIG. 7B shows the synthetic scheme used to generate compounds 6-18 and 23-28 of Formula I.FIG. 7D shows the synthetic scheme used to generate compounds 19-22 of Formula I and compounds 28-40 of Formula III. -
FIG. 8 depicts a sAPPβ assay utilized to identify inhibitors of BACE1. The assay utilizes SY5Y cells stably overexpressing BACE-GFP and SEAP-APPwt. Cells are incubated with a candidate compound for 6 hours prior to harvesting media. BACE1-mediated cleavage of APP results in the release of sAPPβ into the media. α-secretase, a competing enzyme that is non-amyloidogenic, also cleaves APP to release sAPPβ. Using an sAPPβ-specific antibody (sβwt), SEAP-sAPPβ is specifically captured in a modified ELISA assay. Detection is achieved by addition of the fluorescent alkaline phosphatase substrate, 4-methylumbelliferyl phosphate (4-MUP). -
FIG. 9A-B depicts a targeted screen of N-(quinolin-8-yl)benzenesulfonamides, a small-scale screen using 176 structurally-related compounds based on the scaffold of N-(quinolin-8-yl)benzenesulfonamides. A) Primary screen was conducted in 96-well format at 2 μM concentration in duplicate. Data points represent mean of two determinations. The Z′ factors for the four 96-well plates used in the screen were all above 0.7, B) Statistics from the primary screen. The threshold value for hit selection was set at 3 standard deviations, or 59.76%, yielding 6 hit compounds and a hit rate of 3.41%. -
FIG. 10A-B depicts SAR studies of N-(quinolin-8-yl)benzenesulfonamides. 28 full and partial hits, shown in (A) for compounds 1-26 and (B) forcompounds -
FIG. 11A-B depicts Lentiviral-mediated transduction of APPsw in primary neurons. Primary cortical neurons were harvested from wild-type P0 mice and cultured according to established protocols. Lentivirus harboring human Swedish mutant APP (Lenti-APPsw) was packaged using ViraPower Lentiviral Packaging mix (Invitrogen) according to the manufacturer's protocol. DIV-14 neurons were incubated for 24 hours with primary culture media containing the indicated volume (in μl) of virus (LV-1 and LV-2denote 2 separate batches of virus, 0 denotes no virus was used). After infection, neurons were incubated for 72 hours with primary culture media. Media was collected for Aβ40 ELISA (BioSource), and cell lysates were probed with APPCT antibody to visualize transduced full-length APP. (A) Bar graph depicting results; (B) Assay results. -
FIG. 12 depicts immunocytochemistry of primary cortical neurons. DIV-14 primary cortical neurons from wild-type mice were fixed, permeabilized, and stained with TUT I to visualize neuronal β-tubulin (green). Cell nuclei (blue) were visualized with a DAPI co-stain. Cells were imaged with the Nikon C1 digital confocal system at 60× magnification. -
FIG. 13A-B depicts the effect of CU-264 on Aβ expressing primary cortical neuron cultures from wild-type mice transformed with lentivirus harboring APPsw. CU-264, which exhibited sub-micromolar potency for sAPPβ reduction in SY5Y-BACEGFP-SEAPAPPwt cells, does not reduce Aβ40 levels in primary neurons when the cells are incubated with 2 μM CU-264. At 10 μM, CU-264 increased Aβ levels. (A) Bar graph depicting results; (B) Assay results. - For clarity and not by way of limitation, this detailed description is divided into the following sub-portions:
- (i) definitions;
- (ii) synthesis schemes;
- (iii) methods of treatment; and
- (iv) pharmaceutical compositions.
- The terms used in this specification generally have their ordinary meanings in the art, within the context of this invention and in the specific context where each term is used. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the compositions and methods of the invention and how to make and use them.
- In one non-limiting embodiment, the NFκB is a human NFκB. The NFκB is preferably, but not by way of limitation, encoded by the Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFκB1) (GenBank accession number NM—003998), Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) (NFκB2) (GenBank accession numbers NM—001077493, NM—001077494, or NM—002502), Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog A (avian) (RELA) (GenBank accession number NM—021975), Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B (RELB) (GenBank accession number NM—006509), or Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog (avian) (REL) (GenBank accession number NM—002908), or any nucleic acid that encodes a human NFκB polypeptide. Alternatively, NFκB can be encoded by any nucleic acid molecule exhibiting at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or up to 100% homology to any one of the NFκB genes (as determined by standard software, e.g. BLAST or FASTA), and any sequences which hybridize under stringent conditions to these sequences, which retain NFκB activity.
- In other non-limiting embodiments, an NFκB of the invention may be characterized as having an amino acid sequence described by GenBank accession numbers: NP—003989, NP—001070961, NP—001070962, NP—002493, NP—068810, NP—006500, and NP—002899, or any other amino acid sequence at least 90% homologous thereto which retains NFκB activity.
- In another embodiment, NFκB comprises a family of proteins which includes, but is not limited to, the proteins NFκB1 (p50), NFκB2 (p52), RelA (p65), RelB and c-Rel.
- The BACE1, NFκB or APP may be a recombinant BACE1, NFκB or APP polypeptide encoded by a recombinant nucleic acid, for example, a recombinant DNA molecule, or may be of natural origin.
- The term “dysfunction of the immune system” refers to any irregular activation of the innate and adaptive immune response associated with an increase in NFκB activity, for example, aberrant T-cell or B-cell development, maturation, and/or proliferation.
- The term “inflammation” encompasses both acute responses (i.e., responses in which the inflammatory processes are active) as well as chronic responses (i.e., responses marked by slow progression and formation of new connective tissue). In certain non-limiting embodiments, a disease associated with inflammation that is to be treated by a compound of the instant invention is, by way of example, but not by way of limitation, type I hypersensitivity, atopy, anaphylaxis, asthma, osteoarthritis, rheumatoid arthritis, septic arthritis, gout, juvenile idiopathic arthritis, still's disease, ankylosing spondylitis, inflammatory bowel disease, Crohn's disease or inflammation associated with vertebral disc herniation.
- According to the invention, a “subject” or “patient” is a human or non-human animal. Although the animal subject is preferably a human, the compounds and compositions of the invention have application in veterinary medicine as well, e.g., for the treatment of domesticated species such as canine, feline, and various other pets; farm animal species such as bovine, equine, ovine, caprine, porcine, etc.; wild animals, e.g., in the wild or in a zoological garden; and avian species, such as chickens, turkeys, quail, songbirds, etc.
- The term ‘alkyl’ refers to a straight or branched C1-C20, preferably C1-C5, hydrocarbon group consisting solely of carbon and hydrogen atoms, containing no unsaturation, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl).
- The term “alkenyl” refers to a C2-C20, preferably C1-C5, aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be a straight or branched chain, e.g., ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl
- The term “cycloalkyl” denotes an unsaturated, non-aromatic mono- or multicyclic hydrocarbon ring system such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. Examples of multicyclic cycloalkyl groups include perhydronapththyl, adamantyl and norbornyl groups bridged cyclic group or sprirobicyclic groups, e.g., Spiro (4,4) non-2-yl.
- The term “aryl” refers to aromatic radicals having in the range of about 6 to about 14 carbon atoms such as phenyl, naphthyl, tetrahydronapthyl, indanyl, biphenyl.
- The term “heterocyclic” refers to a stable 3- to 15-membered ring radical which consists of carbon atoms and one or more, for example, from one to five, heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. For purposes of this invention, the heterocyclic ring radical may be a monocyclic or bicyclic ring system, which may include fused or bridged ring systems, and the nitrogen, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, a nitrogen atom, where present, may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e., heteroaromatic or heteroaryl aromatic).
- The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
- The term “heteroaryl” refers to a heterocyclic ring wherein the ring is aromatic.
- The substituents in the ‘substituted alkyl’, ‘substituted alkenyl’, ‘substituted cycloalkyl’, ‘substituted aryl,’ ‘substituted heteroaryl’ ‘substituted alkoxy,’ ‘substituted aryloxy,’ ‘substituted alkylthiol,’ and ‘substituted arylthiol’ may be the same or different, with one or more selected from the groups hydrogen, halogen, acetyl, nitro, oxo (═O), CF3, NH2, OCH3, or optionally substituted groups selected from alkyl, alkoxy and aryl.
- The term “halogen” refers to radicals of fluorine, chlorine, bromine and iodine.
- The term “
BACE 1” refers to a polypeptide which mediates the cleavage of APP in the β-amyloidgenic pathway, producing an sAPPβ ectodomain APP metabolite, which is released into the extracellular space, and an intracellular C-terminal fragment (CTF). In one non-limiting embodiment, the BACE1 is a human BACE1. The BACE1 is preferably encoded by the Homo sapiens beta-site APP-cleaving enzyme 1 (BACE1) gene (GenBank accession numbers NM—012104, NM—138972, NM—138971, or NM—138973), or any nucleic acid which encodes a human BACE1 polypeptide. Alternatively, BACE1 can be encoded by any nucleic acid molecule exhibiting at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or up to 100% homology to a BACE1 gene (as determined by standard software, e.g. BLAST or FASTA), and any sequences which hybridize under stringent conditions to these sequences which retain BACE1 activity, where stringent conditions are as described in U.S. Published Patent Application US20030082140, which is hereby incorporated by reference in its entirety and for all purposes. - In other non-limiting embodiments, a BACE1 of the invention may be characterized as having an amino acid sequence described by GenBank accession numbers: NP—036236, NP—620428, NP—620427 and NP—620429, or any other amino acid sequence at least 90%, or at least 95% homologous thereto, which retains BACE1 activity.
- The terms “APP” or “amyloid precursor protein” refers to a substrate of BACE1 which may be metabolized into an ectodomain sAPPβ fragment and a C-terminal fragment (CTF). In one embodiment, APP is an integral membrane protein expressed in many tissues and concentrated in, for example, the synapses of neurons. In one non-limiting embodiment, APP is a human APP, for example, Homo sapiens amyloid beta (A4) precursor protein (APP) encoded by an APP gene (e.g., GenBank Accession numbers: NM—201414, NM—201413, or NM—000484), or any nucleic acid that encodes a human APP polypeptide. Alternatively, APP can be encoded by any nucleic acid molecule exhibiting at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or up to 100% homology to any one of the APP genes (as determined by standard software, e.g. BLAST or FASTA), and any sequences which hybridize under stringent conditions to these sequences.
- In other non-limiting embodiments, APP may be characterized as comprising an amino acid sequence described by GenBank accession numbers: NP—958817, NP—958816, or NP—000475, or any other amino acid sequence at least 90% or at least 95% homologous thereto and is cleavable by a human BACE1 protein. In non-limiting embodiments APP may be comprised in a fusion protein.
- The present invention provides for compounds that inhibit the activity of NFkB and/or BACE1.
- In certain non-limiting embodiments, the invention provides for compounds of the following Formula
- wherein R1, R2, R3, R4, R5 are independently selected for each occurrence from the group consisting of hydrogen, halogen, alkyl, aryl, alkoxy, aryloxy, alkylthiol, arylthiol, CN, and NO2; and
- wherein R10 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted alkenyl.
- In non-limiting embodiments, R1, R2, R3, R4 and R5 are independently selected for each occurrence from the group consisting of hydrogen, methyl, Cl, OCH3, CF3, Br, and F. In a specific non-limiting embodiment, R4 and R5 are hydrogen, and R1, R2, and R3 are independently hydrogen, halogen, alkyl, aryl, CN, alkoxy, aryloxy, NO2, alkylthio, and arylthio.
- In other preferred embodiments, R10 is selected from the group consisting of phenyl, naphthyl, 2-Nitrophenyl, 3-Nitrophenyl, 4-Nitrophenyl, 4-Methyl-2-nitrophenyl, 2-Methyl-5-nitrophenyl, 2-Nitro-4-(trifluoromethyl)phenyl, 4-Methoxy-2-nitrophenyl, 2-Methyl-5-nitrophenyl, 4-Methyl-2-nitrophenyl, 4-Methylphenyl, 2-Aminophenyl, 2-Amino-4-methyl phenyl, Thiophen-2-yl, 5-Chlorothiophen-2-yl, 5-Bromothiophen-2-yl.
- In one non-limiting embodiment, compounds of Formula I may be synthesized according to the following scheme:
- wherein R1, R2, R3, R4, R5 and R10 are defined as above for Formula I.
- In other non-limiting embodiments, compounds of Formula I may be synthesized by any means known in the art.
- In another non-limiting embodiment, the compound defined by Foiinula I is:
- In other non-limiting embodiments, the compound defined by Formula I is:
-
A Compound R1 R2 R3 IC50 (sAPPβ) (μM) CU-131 1-naphthalene H H 6.46 CU-138 1-naphthalene Br H 9.51 CU-150 2-thiophene H H 8.03 CU-151 4-methoxyphenyl H H 5.92 CU-152 4-nitrophenyl H H 4.63 CU-153 2-nitrophenyl H H 1.58 CU-155 2-naphthalene H H 2.20 CU-156 8-quinoline H H 4.23 CU-163 2-naphthalene Br H 0.79 CU-166 phenyl Br H 13.45 CU-167 4-methylphenyl Br H 1.09 CU-168 8-quinoline Br H 17.17 CU-225 4-methylphenyl H Me 3.79 CU-242 2-aminophenyl H H 3.82 CU-261 4-methoxy-2-nitrophenyl H H 1.92 CU-264 4-trifluoromethyl-2-aminophenyl H H 0.53 CU-265 4-trifluoromethyl-2-nitrophenyl H H 2.95 CU-268 2-nitrophenyl OMe H 8.11 CU-271 4-methoxy-2-aminophenyl H H 2.74 CU-273 2-nitrophenyl H Me 12.43 CU-274 2-aminophenyl H Me 11.11 CU-278 4-methoxy-2-aminophenyl H Me 11.48 CU-280 4-trifluoromethyl-2-nitrophenyl H Me 5.51 CU-281 4-trifluoromethyl-2-aminophenyl H Me 3.28 CU-294 2-naphthalene OMe H 3.75 CU-295 1-naphthalene OMe H 3.63 B Compound Structure IC50 (sAPPβ) (μM) CU-262 0.82 CU-282 1.11 - In other non-limiting embodiments, the invention provides for compounds of the following Formula II:
- wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected for each occurrence from the group consisting of hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted alkylthiol, substituted or unsubstituted arylthiol, CN, and NO2. In a specific non-limiting embodiment, R4 and R5 are hydrogen, and R1, R2, and R3 are independently hydrogen, halogen, alkyl, aryl, CN, alkoxy, aryloxy, NO2, alkylthio, and arylthio.
- In a non-limiting embodiment, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected for each occurrence from the group consisting of hydrogen, methyl, Cl, OCH3, CF3 and F.
- In another non-limiting embodiment, the compound defined by Formula II is:
- In another non-limiting embodiment, compounds of Formula II may be synthesized according to the following scheme:
- wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined as above for Formula II.
- In other non-limiting embodiments, compounds of Formula II may be synthesized by any means known in the art.
- In other non-limiting embodiments, the compounds of Formula II may be synthesized according to the following scheme:
- wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined as above for Formula II.
- In other non-limiting embodiments, the invention provides for compounds of the following Formula III:
- wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected for each occurrence from the group consisting of hydrogen, halogen, alkyl, aryl, alkoxy, aryloxy, alkylthiol, arylthiol, CN, and NO2.
- In non-limiting embodiments, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are independently selected for each occurrence from the group consisting of hydrogen, methyl, Cl, OCH3, CF3, OH, and F. In a specific non-limiting embodiment, R4 and R5 are hydrogen, and R1, R2, and R3 are independently hydrogen, halogen, alkyl, aryl, CN, alkoxy, aryloxy, NO2, alkylthio, and arylthio.
- In non-limiting embodiments, compounds of Formula III may be synthesized according to the following scheme:
- wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined as above for Formula III.
- In other non-limiting embodiments, compounds of Formula III may be synthesized by any means known in the art.
- In other non-limiting embodiments, the compounds of Formula III may be synthesized according to the following scheme:
- wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined as above for Formula III.
- In accordance with the invention, there are provided methods of using the compounds of Formulas I-III. The compounds of the instant disclosure can inhibit NFkB activity to exert beneficial effects. A compound of Formula I, II or III that inhibits NFκB activity may be used, in an effective amount, for the treatment of conditions including, but not limited to, cancer, tumorogenesis, and inflammatory conditions including, but not limited to, type I hypersensitivity, atopy, anaphylaxis, asthma, osteoarthritis, rheumatoid arthritis, septic arthritis, gout, juvenile idiopathic arthritis, still's disease, ankylosing spondylitis, inflammatory bowel disease, Crohn's disease or inflammation associated with vertebral disc herniation. A compound of Formula I, II or III that inhibits
BACE 1 activity may be used, in an effective amount, in the treatment of neurodegenerative diseases, such as Alzheimer's disease. In addition, the present invention is directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation. - In non-limiting embodiments, the present invention provides for methods of treating diseases related to dysfunction of cell proliferation, the immune system and/or inflammation in a subject in need of such treatment by administration of a therapeutic formulation which comprises at least one compound of Formulas I-III.
- In particular embodiments, the formulation may be administered to a subject in need of such treatment in an amount effective to inhibit NFkB activity. Where the formulation is to be administered to a subject in vivo, the formulation may be administered systemically (e.g. by intravenous injection, oral administration, inhalation, subcutaneous, intramuscular, etc.), intraventricularly, intrathecally, or by any other means known in the art. The amount of the formulation to be administered may be determined using methods known in the art, for example, by performing dose response studies in one or more model system, followed by approved clinical testing in humans.
- In one embodiment, the subject or patient has been diagnosed with, or has been identified as having an increased risk of developing a disease associated with dysfunction of cell proliferation, the immune system and/or inflammation.
- In other non-limiting embodiments, the present invention provides for methods of reducing in a subject, the risk of inflammatory damage comprising administering to the subject, an effective amount of a composition according to the invention. An effective amount may be a local concentration or, in a pharmaceutical composition, an amount that, when administered to a subject, results in a therapeutic benefit.
- According to the invention, an effective amount is an amount of at least one compound of Formulas I-III which reduces one or more clinical symptom of one or more of the aforementioned diseases. In one example, an effective amount is an amount of at least one compound of Formulas I-III that reduces the activity of NFκB, for example, by stabilizing IκBα or by inhibiting nuclear translocation of NFκB.
- In one non-limiting embodiment, the effective amount of at least one compound of Formulas I-III may be determined, for example, via an in vitro assay wherein the effective amount of a compound of Formulas I-III may be correlated with the compound's ability to stabilize IκBα. By way of example, and not of limitation, such an assay may comprise a cell-based assay designed to identify compounds that stabilize IκBα, and thus reduce nuclear translocation of NFkB. The cell-based in vitro IkBα stabilization assay may utilize a dual reporter system, such as a luciferase reporter system in the cell line OCILy3, a model for primary tumors of the activated B-cell subtype (ABC) of diffuse large B-cell lymphoma (DLBCL) (
FIG. 5 ). The cell line used in the assay may exhibit a high NFκB activity level, for example, constitutive NFkB activity levels due to high levels of IKKβ activity leading to elevated expression of NFkB targeted genes. IKK and proteasome activity may produce high levels of IκBα degradation, liberating NFκB heterodimers to translocate to the nucleus. - According to the assay, modulators of IkBα stability may be identified by measuring changes in the level of expression of an IkBα reporter, for example, an exogenous IkBα-luciferase fusion reporter construct expressed by an NFkB-insensitive promoter. IkBα reporter expression may be measured in the presence or absence of a compound of the invention, wherein a greater increase in IkBα reporter expression by a cell contacted with the compound compared to the IkBα reporter expression in a cell not contacted with the compound is correlative with the therapeutic efficacy of the compound.
- In one example, a dual luciferase IkBα stabilization screen in OCI-Ly3 may be used for high throughput screening (HTS). For example, but not by way of limitation, IkBα fused to a green light-emitting beetle luciferase and a red light-emitting beetle luciferase expressed in a native form can be used to monitor cell uniformity and non-specific effects. Fold-responsiveness may be further increased by having both reporters under the control of inducible promoters, for example, promoters regulated by doxycycline. Upon doxycycline induction of both luciferase reporters, compounds that increased green luminescence with minimal effects on the red luminescence signal may be identified as IkBα stabilizers, and thus an inhibitor of NFκB activity.
- In one non-limiting embodiment, the cell based in vitro IkBα stabilization assay may be the assay depicted in
FIG. 5 a. - In one embodiment, an effective amount of a compound of Formulas I-III may be that amount which stabilizes IkBα, and a greater level of IkBα stabilization at a lower concentration when compared to a control level of IkBα stabilization, for example, as exhibited by a known IkBα stabilizing agent, such as MG-132 (
FIG. 6 ) is correlative with the therapeutic efficacy of the compound. - In one embodiment, the compound may stabilize IkBα with an efficacy of at least about 10-20%, at least about 20-50%, at least about 50-100%, at least about 100-200%, at least about 200-400%, or at least about 400-800% when compared to the IkBα stabilization achieved by a known IkBα stabilizing agent, such as MG-132.
- In one embodiment, an effective amount of a compound of Formulas may be that amount which stabilizes IkBα with an EC50 at a concentration ranging from about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, more preferably from about 50 μM to about 0.01 μM, and more preferably from about 20 μM to about 0.01 μM in the in vitro assay, wherein an EC50 at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- In another non-limiting embodiment, the effective amount of at least one compound of Formulas I-III may be determined, for example, via an in vitro assay wherein the effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the nuclear translocation of NFκB. By way of example, and not of limitation, such an assay may comprise a cell-based assay that utilizes an agent, for example, a cytokine such as TNFα, to stimulate nuclear translocation of endogenous NFkB. Stimulation by the agent may result in proteasome degradation of IkBα and subsequent translocation of NFkB from the cytoplasm to the nucleus, while in the absence of such a stimulatory agent, NFkB is sequestered in the cytoplasm due to its binding to IkBα.
- In the nuclear-translocation in vitro assay, nuclear translocation of NFkB, for example, the endogenous p65 RelA subunit, may be detected and/or measured following stimulation with the agent through the use of, for example, but not limited to, fluorescent antibody detection and an automated imaging platform. Compounds of the invention may be contacted with cells of the in vitro assay, wherein a reduction in NFkB nuclear transport compared to a cell not contacted with the compound is indicative of the compound's ability to inhibit NFκB activity. According to the invention, a reduction in nuclear translocation of NFκB may be correlative with the compound's therapeutic efficacy.
- In one non-limiting embodiment, the cell based nuclear-translocation in vitro assay may be the assay depicted in
FIG. 5 b. - In one embodiment, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to inhibit NFκB nuclear-translocation, wherein a greater level of inhibition at a lower concentration when compared to a control level of inhibition, for example, as exhibited by a known NFiB nuclear-translocation inhibitor, such as BAY 11-7082 (
FIG. 6 ), is indicative of greater therapeutic efficacy of the compound. - In one embodiment, an effective amount of a compound of Formulas I-III may be that amount which inhibits NFκB nuclear-translocation with an efficacy of at least about 10-20%, at least about 20-50%, at least about 50-80%, or at least about 80-100% or more when compared to the NFκB nuclear-translocation inhibition achieved by a known inhibitor, such as BAY 11-7082.
- In one non-limiting embodiment, an effective amount of a compound of Formulas I-III may be that amount which inhibits NFκB nuclear-translocation by at least 50% when the compound is administered at a concentration ranging from about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, more preferably from about 50 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the in vitro assay, wherein inhibition of NFκB nuclear-translocation at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- In another non-limiting embodiment, the effective amount of at least one compound of Formulas I-III may be determined, for example, via an in vitro assay wherein the effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce expression of an NFκB-dependent reporter construct, for example, a β-lactamase reporter (NFκB-bla). By way of example, and not of limitation, such an assay may comprise contacting a cell expressing the NFκB-dependent reporter construct, and monitoring the level of β-lactamase expression, wherein a decrease in expression compared to a cell not contacted with the compound indicates a reduction in NFκB activity. According to the invention, the reduction in expression of the NFκB-dependent reporter may be correlative with the compound's therapeutic efficacy.
- In one non-limiting embodiment, an effective amount of a compound of Formulas I-III may be that amount which reduces expression of an NFκB-bla construct by at least 50% when the compound is administered at a concentration ranging from about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, more preferably from about 50 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the in vitro assay, wherein a reduction of NFκB-bla expression at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- In one non-limiting embodiment, an effective amount of a compound of Formulas I-III may be an amount which achieves a local concentration at the therapeutic site of about 100 μM to about 0.01 μM, preferably from about 50 μM to about 0.01 μM, more preferably from about 20 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the in vitro assay.
- The present invention provides for methods of treating a neurodegenerative disease in a subject in need of such treatment comprising administering, to the subject, a therapeutically effective amount of at least one compound of Formulas I-III. Non-limiting examples of neurodegenerative diseases include Alzheimer's disease, lewy body dementia, inclusion body myositis, and cerebral amyloid angiopathy.
- In particular embodiments, the present invention provides for methods of treating diseases related to metabolism of APP by BACE1 in a subject in need of such treatment by administration of a therapeutic formulation which comprises an effective amount of at least one compound of Formulas I-III. In particular embodiments, the formulation may be administered to a subject in need of such treatment in an amount effective to inhibit BACE1 activity and/or reduce the presence of sAPPβ and/or Aβ. Where the formulation is to be administered to a subject in viva, the formulation may be administered systemically (e.g. by intravenous injection, oral administration, inhalation, etc.), intraventricularly, intrathecally, or by any other means known in the art. The amount of the formulation to be administered may be determined using methods known in the art, for example, by performing dose response studies in one or more model system, followed by approved clinical testing in humans.
- In one embodiment, the subject or patient has been diagnosed with, or has been identified as having an increased risk of developing a neurodegenerative disease, such as Alzheimer's Disease.
- In other non-limiting embodiments, the present invention provides for methods of reducing in a subject, the risk of neural damage comprising administering, to the subject, an effective amount of a composition according to the invention. An effective amount may be a local concentration or, in a pharmaceutical composition, an amount that, when administered to a subject, results in a therapeutic benefit.
- According to the invention, an effective amount is an amount of at least one compound of Formulas I-III which reduces one or more clinical symptom of one or more of the aforementioned diseases. In one example, an effective amount is an amount of at least one compound of Formulas I-III that reduces the production of sAPPβ or Aβ generated by the metabolism of APP by BACE1.
- In one non-limiting embodiment, the effective amount of at least one compound of Formulas I-III may be determined via an in vitro assay, for example, as described in International Patent Application No. PCT/US2007015938 (Publication No. WO 2008008463), which is incorporated in its entirety herein for all purposes, wherein the effective amount may be correlated with the compound's ability to reduce the level of sAPPβ. By way of example, and not of limitation, such an assay may comprise a cell-based modified ELISA assay for measuring sAPPβ, the secreted ectodomain of β-amyloid precursor protein (APP) following β-secretase (BACE1) cleavage. Such an in vitro assay may be used to identify compounds of Formulas I-III that interfere with the first step of sAPPβ generation.
- As described in the Examples below, and depicted in
FIG. 8 , the sAPPβ ELISA assay may comprise cells, for example, SY5Y cells, transfected with a BACE1 reporter construct, such as a GFP-tagged BACE 1 (BACE-GFP), and a wild type APP reporter construct, such as a secreted alkaline phosphatase (SEAP)-tagged wild type APP (SEAP-APPwt).BACE 1 cleavage of the reporter-tagged APP (e.g. SEAP-APPwt) may result in secretion into the media of SEAP-tagged sAPPβ, which may be collected and specifically captured using an sAPPβ cleavage site-specific antibody (e.g. sβwt). Following washing, a substrate may be used, for example, the fluorescent alkaline phosphatase substrate 4-methylumbelliferyl phosphate (4-MUP), to detect the captured SEAP-sAPPβ. - In one non-limiting example, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the level of sAPPβ detected in the in vitro assay compared to a control cell culture that was not contacted with the candidate compound, wherein a reduction of sAPPβ compared to the control cell culture correlates with the compound's therapeutic efficacy.
- In another non-limiting example, an effective amount of a compound of Formulas I-III may be that amount which reduces the level of sAPPβ detected in the in vitro assay by at least 0.1, or by at least 0.5, or by at least 1, or by at least 1.5, or by at least 2, or by at least 2.5, or by at least 3, or by at least 3.5, or by at least 4, or by at least 4.5, or by at least 5, or by at least 5.5, or by at least 6 or more standard deviations above a control level of sAPPβ reduction detected in the in vitro assay when the compound is tested at a concentration of about 2 μM, or about 10 μM, wherein such a reduction of sAPPβ correlates with a compound's therapeutic efficacy. In one embodiment, the control level of sAPPβ reduction may be the average sAPPβ level in control cell cultures that are not contacted with the candidate compound. In other embodiments, the control level may be the average level of sAPPβ reduction achieved by a series of compounds tested in the in vitro assay.
- In one preferred non-limiting embodiment, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce sAPPβ levels by about 3 standard deviations greater than a control level of sAPPβ reduction when the compound is administered at a concentration of 2 μM in the in vitro assay.
- In other preferred non-limiting embodiments, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPPβ level by about 3 standard deviations greater than a control level of sAPPβ reduction when the compound is administered at a concentration of 10 μM in the in vitro assay.
- In another example, an effective amount of a compound of Formulas may be that amount which reduces the level of sAPPβ by at least 5%, by at least 10%, by at least 20%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 80%, by at least 90%, or by 100% when compared to sAPPβ level in a control cell culture that was not contacted with the candidate compound, wherein such a reduction of sAPPβ correlates with a compound's therapeutic efficacy.
- In another example, an effective amount of a compound of Formulas may be that amount which reduces the level of sAPPβ by at least about 50% compared to a control cell culture that was not contacted with the candidate compound, wherein the compound is tested at a concentration ranging from about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the in vitro assay, wherein such a reduction of sAPPβ at the above-described concentrations is correlative with the compound's therapeutic efficacy.
- In other preferred non-limiting embodiments, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPPβ level by about at least 50% when the compound is administered at a concentration of about 0.5 μM in the in vitro assay.
- In other preferred non-limiting embodiments, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPPβ level by about at least 50% when the compound is administered at a concentration of about 1 μM in the in vitro assay.
- In other preferred non-limiting embodiments, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPPβ level by about at least 50% when the compound is administered at a concentration of about 2 μM in the in vitro assay.
- In other preferred non-limiting embodiments, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPPβ level by about at least 50% when the compound is administered at a concentration of less than 3 μM in the in vitro assay.
- In other preferred non-limiting embodiments, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPPβ level by about at least 50% when the compound is administered at a concentration of about 5 μM in the in vitro assay.
- In other preferred non-limiting embodiments, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPPβ level by about at least 50% when the compound is administered at a concentration of about 8 μM in the in vitro assay.
- In other preferred non-limiting embodiments, an effective amount of a compound of Formulas I-III may be correlated with the compound's ability to reduce the sAPPβ level by about at least 50% when the compound is administered at a concentration of about 10 μM in the in vitro assay.
- In other non-limiting embodiments, the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to inhibit the enzymatic activity of a BACE1 enzyme. The compound's BACE1 inhibitory effect may be assayed, for example, through use of a BACE1 FRET Assay kit (Invitrogen Corp., Carlsbad, Calif., U.S.A.), wherein the fluorescence resonance energy transfer (FRET)-based assay measures the cleavage by purified recombinant β-secretase of a peptide substrate corresponding to the BACE1 cleavage site of Swedish mutant APP. In such an assay, a greater reduction in fluorescence in the reaction mixture following incubation with a compound of the invention compared to a control cell culture not contacted with the compound is correlative with the compound's therapeutic efficacy.
- In one example, an effective amount of a compound of Formulas I-III may be that amount which inhibits BACE1 enzymatic activity by at least about 50% compared to a control cell culture that was not contacted with the candidate compound. Preferably the compound is tested at a concentration ranging from about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the in vitro assay, wherein such an inhibition of BACE1 enzymatic activity at the above-described concentrations is correlative with the compound's therapeutic efficacy.
- In other non-limiting embodiments, the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of Aβ40 in an in vitro assay that measures the level of Aβ40 produced in a cell line, for example, an SY5Y-BACEGFP-SEAPAPPwt cell line. In one non-limiting example, the level of Aβ40 expressed by the cell line may be measured through the use of an Aβ40 Elisa kit (BioSource). In one embodiment, the assay comprises incubating the Aβ40 expressing cells with a compound of Formulas I-III, followed by assaying the concentration of Aβ40 in the cell culture medium. In such an assay, a greater reduction of Aβ40 concentration in the cell culture medium following incubation with a compound compared to a control cell culture not contacted with the compound is correlative with the compound's therapeutic efficacy.
- In one example, an effective amount of a compound of Formulas I-III may be that amount which reduces the level of Aβ40 in an in vitro assay by at least about 50% compared to a control cell culture that was not contacted with the candidate compound. Preferably the compound is tested at a concentration ranging from about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the in vitro assay, wherein such a reduction in the level of Aβ40 at the above-described concentrations is correlative with the compound's therapeutic efficacy.
- In other non-limiting embodiments, the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of Aβ40 in an in vitro assay that measures the level of Aβ40 produced in a cell culture, for example, a culture of primary cortical neurons transduced with lentivirus carrying Swedish mutant APP (APPsw). In one embodiment, the assay comprises incubating the Aβ40 expressing cells with a compound of Formulas I-III, followed by assaying the concentration of Aβ40 in the cell culture medium. In such an assay, a greater reduction of Aβ40 concentration in the cell culture medium following incubation with a compound compared to a control cell culture not contacted with the compound is correlative with the compound's therapeutic efficacy.
- In one non-limiting embodiment, an effective amount of a compound of Formulas I-III may be that amount which reduces Aβ40 by about 1-10%, more preferably from about 10-20%, more preferably from about 20-30%, more preferably from about 30-40%, more preferably from about 40-50%, more preferably from about 50-60%, more preferably from about 60-70%, more preferably from about 70-80%, more preferably from about 80-90%, and more preferably from about 90-100%, compared to Aβ40 levels in the cell culture medium of a control cell culture that was not incubated with the compound. Preferably the compound is incubated at a concentration of about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the in vitro assay, wherein a greater level of Aβ40 reduction at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- In other non-limiting embodiments, the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of sAPPβ in an in vitro assay that measures the level of sAPPβ produced in a cell culture, for example, primary cortical neurons transduced with lentivirus carrying Swedish mutant APP (APPsw). In one embodiment, the assay comprises incubating the cells with a compound of Formulas I-III, followed by assaying the concentration of sAPPβ in the cell culture medium. In such an assay, a greater reduction of sAPPβ concentration in the cell culture medium following incubation with a compound compared to a control cell culture not contacted with the compound is correlative with the compound's therapeutic efficacy.
- In one non-limiting embodiment, an effective amount of a compound of Formulas I-III may be that amount which reduces sAPPβ by about 1-10%, more preferably from about 10-20%, more preferably from about 20-30%, more preferably from about 30-40%, more preferably from about 40-50%, more preferably from about 50-60%, more preferably from about 60-70%, more preferably from about 70-80%, more preferably from about 80-90%, and more preferably from about 90-100%, compared to sAPPβ levels in the cell culture medium of a control cell culture that was not incubated with the compound. Preferably the compound is incubated at a concentration of about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the in vitro assay, wherein a greater level of sAPPβ reduction at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- In other non-limiting embodiments, an effective amount of a compound of Formulas I-III may be that amount which reduces Aβ40 by about 50% in an in vitro assay compared to Aβ40 levels in the cell culture medium of a control cell culture that was not incubated with the compound. Preferably the compound is incubated at a concentration of about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, and more preferably from about 10 μM to 0.01 μM in the in vitro assay, wherein a reduction of Aβ40 at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- In other non-limiting embodiments, the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of Aβ40 in an in vitro assay that measures the level of Aβ40 produced in a cell culture, for example, cultured primary cortical neurons prepared from Tg2576 mice (i.e. mice carrying human APPsw transgene under the control of the PrP promoter). In one embodiment, the assay comprises incubating the Aβ40 expressing cells with a compound of Formulas I-III, followed by assaying the concentration of Aβ40 in the cell culture medium. In such an assay, a greater reduction of Aβ40 concentration in the cell culture medium following incubation with a compound compared to a control cell culture not contacted with the compound is correlative with the compound's therapeutic efficacy.
- In one non-limiting embodiment, an effective amount of a compound of Formulas I-III may be that amount which reduces Aβ40 by about 1-10%, more preferably from about 10-20%, more preferably from about 20-30%, more preferably from about 30-40%, more preferably from about 40-50%, more preferably from about 50-60%, more preferably from about 60-70%, more preferably from about 70-80%, more preferably from about 80-90%, and more preferably from about 90-100%, compared to Aβ40 levels in the cell culture medium of a control cell culture that was not incubated with the compound. Preferably when the compound is incubated at a concentration of about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the in vitro assay, wherein a greater level of Aβ40 reduction at a lower concentration in the in vitro assay is correlative with the compound's therapeutic efficacy.
- In other non-limiting embodiments, the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of Aβ40 and/or sAPPβ in an ex vivo assay that measures the level of Aβ40 and/or sAPPβ produced in cells, for example, organotypic brain slices from Tg2576 mice (i.e. mice carrying human APPsw transgene under the control of the PrP promoter). In one embodiment, the assay comprises incubating the brain slices with a compound of Formulas followed by assaying the concentration of Aβ40 and/or sAPPβ in the brain slices. In such an assay, a greater reduction of Aβ40 and/or sAPPβ concentration in the brain slices following incubation with a compound compared to a control brain slice not contacted with the compound is correlative with the compound's therapeutic efficacy.
- In one non-limiting embodiment, an effective amount of a compound of Formulas I-III may be that amount which reduces Aβ40 and/or sAPPβ by about 1-10%, more preferably from about 10-20%, more preferably from about 20-30%, more preferably from about 30-40%, more preferably from about 40-50%, more preferably from about 50-60%, more preferably from about 60-70%, more preferably from about 70-80%, more preferably from about 80-90%, and more preferably from about 90-100%, compared to Aβ40 and/or sAPPβ levels in control brain slices that were not incubated with the compound. Preferably the compound is incubated at a concentration of about 200 μM to about 0.01 μM, preferably from about 100 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the ex vivo assay, wherein a greater level of Aβ40 and/or sAPPβ reduction at a lower concentration in the ex vivo assay is correlative with the compound's therapeutic efficacy.
- In other non-limiting embodiments, the effective amount of at least one compound of Formulas I-III may be correlated with the compound's ability to reduce the level of Aβ40 and/or sAPPβ in an in vivo assay that measures the level of Aβ40 and/or sAPPβ produced in a test subject, for example, a Tg2576 mouse (i.e. mice carrying human APPsw transgene under the control of the PrP promoter). In one embodiment, the assay comprises administering at least one compound of Formulas I-Ill to the test subject, for example, via interstitial fluid (ISF) compound administration, intraperitoneal (IP) compound injection, or through the use of a microdialysis apparatus for infusion of the compound at multiple concentrations (for example, in the hippocampus of the test subject), followed by assaying the concentration of Aβ40 and/or sAPPβ in the test subject. In such an assay, a greater reduction of Aβ40 and/or sAPPβ concentration in the test subject following administration of the compound compared to a control subject not administered the compound is correlative with the compound's therapeutic efficacy.
- In one non-limiting embodiment, an effective amount of a compound of Formulas I-III may be that amount which reduces Aβ40 and/or sAPPβ by about 1-10%, more preferably from about 10-20%, more preferably from about 20-30%, more preferably from about 30-40%, more preferably from about 40-50%, more preferably from about 50-60%, more preferably from about 60-70%, more preferably from about 70-80%, more preferably from about 80-90%, and more preferably from about 90-100%, compared to Aβ40 and/or sAPPβ levels in brain homogenates of subjects that were not administered the compound. Preferably the compound is administered at a concentration of about 0.5 mg/kg to about 20 mg/kg, preferably from about 1 mg/kg to about 20 mg/kg, more preferably from about 3 mg/kg to about 20 mg/kg, more preferably from about 5 mg/kg to about 20 mg/kg, more preferably from about 10 mg/kg to about 20 mg/kg in the in vivo assay, wherein a greater level of Aβ40 and/or sAPPβ reduction at a lower concentration in the in vivo assay is correlative with the compound's therapeutic efficacy.
- In non-limiting embodiments, an effective amount of a compound of Formulas I-III may be an amount which achieves a local concentration at the therapeutic site of about 100 μM to about 0.01 μM, preferably from about 50 μM to about 0.01 μM, more preferably from about 20 μM to about 0.01 μM, and more preferably from about 10 μM to about 0.01 μM in the in vitro assay.
- According to the invention, the component or components of a pharmaceutical composition of the invention may be administered to a subject by means including but not limited to intravenous, intra-arterial, intramuscular, intradermal, transdermal, subcutaneous, oral, intraperitoneal, intraventricular, and intrathecal administration.
- In particular non-limiting embodiments, the therapeutic compound can be delivered in a controlled or sustained release system. For example, a compound or composition may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In one embodiment, a pump may be used (see Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201; Buchwald et al., 1980, Surgery 88:507; Saudek et al., 1989, N. Engl. J. Med. 321:574). In another embodiment, polymeric materials can be used (see Langer and Wise eds., 1974, Medical Applications of Controlled Release, CRC Press: Boca Raton, Fla.; Smolen and Ball eds., 1984, Controlled Drug Bioavailability, Drug Product Design and Performance, Wiley, N.Y.; Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem., 23:61; Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neural., 25:351; Howard et al., 9189, J. Neurosurg. 71:105). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the heart or a blood vessel, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical Applications of Controlled Release, supra, Vol. 2, pp. 115-138). Other controlled release systems known in the art may also be used.
- The compounds and compositions of the invention may be formulated as pharmaceutical compositions by admixture with a pharmaceutically acceptable carrier or excipient.
- For example, the pharmaceutical composition may comprise an effective amount of at least one compound of Formulas I-III and a physiologically acceptable diluent or carrier. The pharmaceutical composition may further comprise a second drug, for example, but not by way of limitation, an anti-cancer drug, an anti-inflammatory drug, for example, but not limited to, a steroid compound and/or a non-steroidal anti-inflammatory drug, or compound for the treatment of Alzheimer's disease, such as an acetylcholinesterase inhibitor or an NMDA glutamate receptor antagonist (e.g. memantine).
- The phrase “pharmaceutically acceptable” indicates that a substance is physiologically tolerable when administered to a subject. Preferably, but not by way of limitation, as used herein, the term “pharmaceutically acceptable” means approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, or, for solid dosage forms, may be standard tabletting excipients. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin, 18th Edition, or other editions.
- In a specific embodiment, the therapeutic compound can be delivered in a vesicle, in particular a liposome (see Langer, 1990, Science 249:1527-1533; Treat et al., 1989, in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler eds., Liss: New York, pp. 353-365; Lopez-Berestein, ibid., pp. 317-327; see generally Lopez-Berestein, ibid.).
- The present invention is not to be limited in scope by the specific embodiments described herein and the Examples that follow. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying Examples and Figures. Such modifications are intended to fall within the scope of the appended claims.
- Patents, patent applications, publications, product descriptions, GenBank Accession Numbers, and protocols are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties for all purpose.
- The compounds of Formulas I and II consist of N-(quinolin-8-yl)benzensulfonamides, and the compounds of Formula III consist of a structurally constrained cyclic sulfonamide with the sultam bridging quinolinyl and phenyl moieties. This particular scaffold lacks a general synthetic method. Described here is an efficient synthesis of this class of compounds that allows a diverse substitution pattern.
- The synthetic strategy was to generate N-8-quinolinyl benzenesulfonamides, and then construct the sultam skeleton through cyclization of the easily accessible N-8-quinolinyl benzenesulfonamides. Diazotization-induced cyclization was employed to synthesize the target compound (
FIG. 2 ).Sulfonamide 8 was prepared from 2-nitrobezenesufonyl chloride and 8-aminoquinoline 2 in pyridine. The nitro group was reduced with SnCl2 to provideamine 9 and subsequent diazotization affordedtriazine 10. A procedure employing Cu (0) and NaOH (Ullman et al., 1911, Ber. Dtsch. Chem. Ges. 43:2694), failed to yield the desired product, but thermolysis in a variety of solvents (e.g. EtOH, H2O, DMSO or HOAc) or neat afforded theproduct 1. The best result (41% yield) was obtained by heating in glacial acetic acid at 120° C. for ten minutes. - A second synthetic method involves a one-pot synthesis of N-8-quinolinyl benzenesultams from N-8-quinolinyl-2-aminobezenesulfonamides. In a typical reaction, as shown in
FIG. 3A , 2-aminobenzenesulfonamide 9a, prepared from 6-methoxy-2-methylquinolin-8-amine 2a (Qiu et al., 2007, Inorg. Chim. Acta. 360:431), was dissolved in HOAc and treated with 1.5 equiv of t-BuONO at 10° C. The reaction was allowed to warm to room temperature over 10 minutes and afforded sultam 1a in (78% yield) without isolation of the triazine intermediate. - A selection of N-8-quinolinyl-2-aminobezenesulfonamides (9a-p) were prepared and subsequently cyclized in similar one-pot reactions to give sultams (1a-p) (
FIG. 4 ). In each case, the product was isolated without intermediate purification (FIG. 4 ). Aminobezenesulfonamides (9b-h and 9l-p) were synthesized in a similar manner described inFIG. 3A .Intermediates 9i-k were prepared fromaniline 11 as outlined inFIG. 3B : Sulfonamidation ofaniline 11 with 2-nitrobezenesufonyl chloride providedsulfonamide 12. Skraup reaction under modified conditions (Matsugi et al., 2000, Tetrahedron Lett. 41:8523) followed by reduction of nitro group provided the N-quinolinyl sulfonamides (9i-k). - A typical synthesis of a compound of Formulas II and III involves the following steps:
-
Compound 9a: To a solution of 6-methoxy-2-methylquinolin-8-amine 2a (0.19 g, 1.0 mmol) in pyridine (5 ml) was added 4-methyl-2-nitrobenzenesulfonyl chloride (0.24 g, 1.0 mmol). The mixture was stirred at room temperature overnight and precipitated with H2O. The crude product was filtered and recrystallized from EtOH to afford nitrobenzenesulfonamide (0.31 g, 79%) as red crystal. 1H NMR (300 MHz, CDCl3) δ 10.1 (br, 1H); 8.04 (d, 1H), 7.86 (d, 1H), 7.62 (m, 2H), 7.39 (d, 1H), 7.24 (d, 1H), 6.73 (s, 1H), 3.88 (s, 31-1), 2.66 (s, 3H), 2.41 (s, 3H); ESI-MS (M±±1): 388.0. To a suspension of above nitro compound (0.20 g, 0.56 mmol) in EtOH (5 ml) was added SnCl2 (0.32 g, 1.7 mmol) slowly. The mixture was refluxed for 2 h. After removal of EtOH, the residue was treated with 1M NaOH. The aqueous solution was extracted with CH2Cl2. The combined organic phases were washed by brine, dried over Na2SO4, and concentrated to yield 9a (0.18 g, 92%) as white solid. 1H NMR (300 MHz, CDCl3) δ 9.42 (br, 1H); 7.83 (d, 1H), 7.65 (d, I H), 7.30 (s, 1H), 7.23 (d, 1H), 6.64 (s, 1H), 6.48 (d, 1H), 6.42 (s, 111), 3.80 (s, 3H), 2.61 (s, 3H), 2.17 (s, 3H); ESI-MS (M++1): 358.1. - Compound 1a:
- To a solution of 9a (0.1 g, 0.28 mmol) in HOAc (1 ml) at 10° C. was added t-BuONO (0.05 mL, 0.42 mmol). The reaction was slowly warmed to room temperature over 10 min and quenched with H2O. The mixture was extracted with EtOAc. The combined organic phases were washed with saturated NaHCO3, dried over Na2SO4, and concentrated. Flash chromatography (EtOAc/CH2Cl2 1:10 vv) gave 1a (74 mg, 78%) as yellow solid. 1H NMR (300 MHz, CDCl3) δ 8.49 (s, 1H), 7.98 (d, 1H), 7.92 (d, 1H), 7.37 (d, 114), 7.25 (d, 1H), 6.87 (s, 1H), 4.00 (s, 3H), 2.69 (s, 3H), 2.52 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 156.2, 155.2, 142.2, 134.8, 134.5, 134.1, 132.2, 131.4, 130.1, 129.0, 126.8, 124.4, 122.0, 112.5, 100.0, 56.2, 25.2, 22.6; ESI-MS (M++1): 341.2.
- In summary, a one-pot reaction for the conversion of N-8-quinolinyl-2-aminobezenesulfonamides into their corresponding sultams under mild conditions has been described. This procedure offers access to a class of heterocyclic compounds that have shown therapeutic potential as novel BACE1 and NF-κB inhibitors, as described below.
- Small molecule regulation of signaling cascades associated with NFkB may provide novel approaches to alleviate numerous disease states, (D'Acquisto, et al., 2006 Curr. Opin. Pharmacol. 6:387; Gilmore, et al., 2006, Oncogene 25:6887). Several high-throughput campaigns in search of novel inhibitors of the NFkB signal transduction pathway have been undertaken. Two of these include a cell-based assay designed to identify IkBα stabilization, and a cell-based assay designed to identify inhibitors of TNFα-induced translocation of NFkB. Despite the differing assay design, cell type, and signal readout, a N-(quinolin-8-yl)benzenesulfonamide core scaffold was identified in both screens.
- The first assay, an IkBα stabilization screen, was performed using a dual luciferase reporter system in the cell line OCILy3, an excellent model for primary tumors of the activated B-cell subtype (ABC) of diffuse large B-cell lymphoma (DLBCL) (Figure SA; PubChem AID: 445) (Davis, et al., 2007, Drug Dev. Technol. 5:85; Davis, et al., 2001, J. Exp. Med. 184:1861; Okamoto, et al., 2007, Curr. Pharm. Des. 13:447) Abnormally high constitutive NFkB activity levels have been noted in ABC-DLBCL, as in several types of cancer, due to high levels of IKK13 activity leading to elevated expression of NFkB targeted genes. (Okamoto, et al., 2007, Curr. Pharm. Des. 13:447) In this setting, IKK and proteasome activity produce high degradation of IkBα, liberating p50/65 and/or p50/c-Rel heterodimers to translocate to the nucleus. Because lines of ABC-DLBCL and other cancer types are dependent on constitutive NFkB activity, the NFkB pathway is a therapeutic target. This is particularly true for those processes governing IkBα degradation, and the therapeutic potential of small molecules for this purpose has been shown by studies in ABC-DLBCL lines using a specific IKKβ inhibitor. Furthermore, the use of an ABC-DLBCL line for a small-molecule screen of IkBα stabilization provides a context that is especially close to that of the targeted disease, with the potential that inhibitors may be found that affect specific upstream points in IKK activation.
- To identify modulators of IkBα stability in ABC-DLBCL lines, such as small molecules inhibiting IKK or proteasome activity, changes in the level of an exogenous IkBα-luciferase fusion reporter expressed by an NFkB-insensitive promoter were measured. (Lam et al., 2005, Clin. Cancer res. 11:28; Ngo et al., 2006, Nature 441:106) The dual luciferase IkBα stabilization screen in OCI-Ly3 employed was designed to be suitable for HTS, by using IkBα fused to a green light-emitting beetle luciferase, with a red light-emitting beetle luciferase expressed in a native form to monitor cell uniformity and non-specific effects. (Davis, et al., 2007, Drug Dev. Technol. 5:85) Fold-responsiveness was further increased by having both reporters under the control of inducible promoters regulated by doxycycline. Upon doxycycline induction of both luciferase reporters, compounds that increased green luminescence with minimal effects on the red luminescence signal were scored as IkBα stabilizers. (Davis, et al., 2007, Drug Dev. Technol. 5:85).
- The second assay, a translocation-based assay, was a high-content screen performed in human umbilical vein endothelial cells (HUVEC) using TNFα to stimulate nuclear translocation of endogenous NFkB (Figure SB; PubChem AID: 438). NFkB is sequestered in the cytoplasm due to its binding to IkBα, which blocks exposure of a nuclear localization sequence. Activation by cytokines such as TNFα results in proteasome degradation of IkBα and subsequent translocation of NFkB from the cytoplasm to the nucleus. In the assay, nuclear translocation of the endogenous p65 RelA subunit of NFkB, at 30 min post-stimulation, was monitored using fluorescent antibody detection and an automated imaging platform. (Mayer et al., 2006, Methods Enzyme 414:266) NFkB inhibitors in this assay, such as IkBα stabilizers, were detected as compounds that interfered with p65 translocation to the nucleus.
- The above-described assays were validated using known inhibitors of the NFkB pathway (
FIG. 6 ). The proteasome inhibitor MG-132 (1) 16 served as a positive control for the IkBα stabilization assay. The translocation assay used BAY 11-7082 (2), an agent that inhibits the TNFα-induced phosphorylation of IkBα. (Kamthong, 2001, Biochem 356:525; Izban et al., 2000, Hum. Pathol. 31:1482; Pierce et al., 1997, J. Biol. Chem. 272:21096). Additionally, a substituted 2-(thiophen-2-yl)quinazoline 3 which acts as an inhibitor of NFkB and AP1 mediated transcriptional activation (Palanki et al., 2003, Bioorg. Med. Chem. Lett. 13:4077) was used as a positive control in a secondary assay that used TNFα to stimulate NFkB-dependent expression of a β-lactamase reporter (NFkB-bla inFIG. 7 ). This compound also served as a negative control for the dual luciferase IkBα stabilization assay. - N-(quinolin-8-yl)benzenesulfonamide (4) and the related C7-locked N-(quinolin-8-yl)benzenesulfonamide (5) were identified as two common structures in both screens (
FIG. 6 ). To further confirm that these agents interfered with the NFkB activation in a genuine manner, a reporter assay obtained from Invitrogen where induction of β-lactamase occurred in an NFkB-dependent manner was also performed on the active compounds. These data confirmed the ability of these compounds to inhibit the NFkB pathway, and the compounds were then advanced for further study (FIG. 7 ). - The synthesis of analogues of (4) was undertaken through a one-step process involving the addition of unsubstituted or 2-substituted, 6-substituted or 2,6-disubstituted quinolin-8-amines and a variety of sulfonyl chlorides (
FIG. 7B ). Amino-substituted analogues (19-22) (Izban et al., 2000, Hum. Pathol. 31:1482) were obtained by reduction of the corresponding nitro compounds with stannous chloride in ethanol (FIG. 7D ). Over 40 novel analogues were prepared to establish preliminary structure activity relationships. - The synthesis of various analogues of (5) via a diazotization-induced cyclization of accessible N-8-quinolinyl-2-aminobenzenesulfonamides proved to be an efficient way of synthesizing this type of C7-locked sulfonamide (
FIG. 7D ). - Analogues of (4) and (5) were analyzed within both screens. Results for analogues of (4) are shown in
FIG. 7A , while the results for derivatives of (5) are shown inFIG. 7C . In general, there was agreement in the relative potencies of analogues tested in both screening assays, as well as the NFkB β-lactamase reporter assay (although exceptions do exist). - A more rigid structure was associated with
compound 5, because a bridge between the quinoline carbon 7 and the ortho-position of the sulfonyl phenyl ring locks the core scaffold in a rigid conformation. Two compounds (30 and 31) with the best overall potency values were identified here. Substituents at the 9 position (para to the sulfonylamide moiety designated R′″ inFIG. 7C ) are generally well tolerated as are 6-methoxy and 2-methyl substitutions (analogues 32 and 37-40, respectively). - A cell-based modified ELISA assay for measuring sAPPβ, the secreted ectodomain of β-amyloid precursor protein (APP) following β-secretase (BACE 1) cleavage, was used to identify a class of compounds that interfered with the first step of sAPPβ generation. This assay has been described in International Application PCT/US2007015938 (Published as International Publication No. WO 08/008463), which is herein incorporated in its entirety for all purposes.
- BACE1-mediated cleavage of APP is a key and necessary event in the generation of neurotoxic β-amyloid (Aβ), a widely accepted contributor to the development of Alzheimer's disease (AD). Studies in
BACE 1 knockout mice showed that they are viable, fertile, and do not produce Aβ, making BACE1 an attractive target for AD therapeutic intervention. - The SY5Y-BACEGFP-SEAPAPPwt cell based assay was developed to discover novel small molecule modulators of BACE1 activity. SY5Y cells were stably transfected with GFP-tagged BACE1 (BACE-GFP) and secreted alkaline phosphatase (SEAP)-tagged wildtype APP (SEAP-APPwt). BACE1 cleavage of SEAP-APPwt results in secretion into the media of SEAP-tagged sAPPβ, which is collected and specifically captured using an sAPPβ cleavage site-specific antibody (sβwt). After washing, the fluorescent alkaline phosphatase substrate 4-methylumbelliferyl phosphate (4-MUP) is used to detect the captured SEAP-sAPPβ (
FIG. 8 ). - N-(quinolin-8-yl)benzenesulfonamides (
FIG. 2 ) were recently reported as agents capable of down-regulating NF-κB activity (Xie et al., 2008). NF-κB is a ubiquitous transcription factor that is thought to play a role in many cellular processes, including immune and inflammatory responses, developmental processes, cellular growth, and apoptosis. Dysregulation of NF-κB signaling has been associated with many disease states, including asthma, arthritis, cancer, inflammatory conditions, neurodegenerative diseases, and heart disease (reviewed in Kumar et al., 2004). NF-κB inhibitors have also been reported to inhibit Ap production (Paris et al., 2007). Furthermore, N-(quinolin-8-yl)benzenesulfonamides bear structural similarity to clioquinol and its second-generation compound PBT2. Both clioquinol and PBT2 are believed to be strong metal ion chelators that may interfere with oligomerization and aggregation of AP and promote its clearance (Ritchie et al., 2003). PBT2, developed by Prana Biotechnology, is currently in Phase II clinical trial for the treatment of AD. Thus, a small library of N-(quinolin-8-yl)benzenesulfonamides and related compounds was screened for agents that reduce BACE1-mediated cleavage of APP. - 176 compounds were tested in the primary screen (
FIG. 9 ). Briefly, each compound (10 mM stock in DMSO) was diluted 1:25 in DMSO and loaded onto 96-well plates to generate a 400 μM stock plate. 1 μl of each compound was then diluted 1:200 with cell culture media (0.5% DMSO concentration) in two separate 96-well plates for a final screening concentration of 2 μM. 150 μl of media containing compound was then transferred onto SY5Y-BACEGFP-SEAPAPPwt cells in 96-well format, and the BACE1 assay was performed as described previously. The primary screen was conducted in duplicate. A parallel screen was conducted at 10 μM concentration, also in duplicate. This data is not shown. Percent inhibition of the fluorescence signal was calculated as 100×[DMSO control compound]/DMSO control The majority of data points were clustered between −25% and 25% inhibition of sAPPβ fluorescence signal (FIG. 9A ). The Z′ factors for all 4 96-well plates used in the primary screen were above 0.7 (data not shown). The threshold for hit selection was set at 3 standard deviations, or 59.76% inhibition, yielding 6 small molecule hits and a hit rate of 3.41% (FIG. 9B ). - Several partial hits were also identified in the targeted screen of N-(quinolin-8-yl)benzenesulfonamides. Partial hits were defined loosely as compounds that either exhibited activity just below the threshold 59.76% inhibition in the 2 μM screen or those that displayed significant activity in the 10 μM screen. These compounds were characterized for 8-point dose-response and structure-activity relationship studies.
- In summary, a cell-based BACE1 assay was used to screen N-(quinolin-8-yl)benzene-sulfonamides and related compounds, a class of NF-κB inhibitors. Because of their potency, availability, and the reported connection between NF-κB inhibition and AP generation, structural analogs of N-(quinolin-8-yl)benzenesulfonamides were also selected for investigation in structure-activity relationship studies. Primary and secondary screening using the cell-based BACE1 assay thus yielded chemotypes for SAR studies and further characterization in more physiological systems.
- SAR studies were conducted for full and partial hits from the targeted screen of N-(quinolin-8-yl)benzenesulfonamides. Characterization in SY5 Y-BACEGFP-SEAPAPPwt cells identified CU-264 as the most potent analog. CU-264 was further characterized in a of more physiological assay for its ability to reduce Aβ40 and sAPPβ. CU-264 had the effect of raising Aβ40 and sAPPβ levels.
- SAR Studies of N-(quinolin-8-yl)Benzenesulfonamides
- Targeted screening of N-(quinolin-8-yl)benzenesulfonamides and related compounds revealed several full and partial hits capable of reducing the fluorescent signal from the cell-based BACE1 assay. Based on the chemical structures of the 176 compounds as well as the full and partial hits from the targeted screen, the structural elements that were critical for activity were identified. All full and partial hits contained the sulfonamide of quinoline motif either in open or cyclized varieties, as shown in
FIG. 10 . Substituting naphthalene for quinoline or removal of the sulfonamide substituent resulted in loss of activity. - 28 full and partial hits were characterized in 8-point dose-response experiments for IC50 determination in SY5Y-BACEGFP-SEAPAPPwt cells (
FIG. 10 ). The investigation revealed 3 compounds with sub-micromolar potencies for sAPP3 reduction—CU-163, CU-264, and CU-262. Analysis of the data revealed a few structure-activity relationships. Addition of a methyl group at R3 resulted in a reduction of potency (compare CU-274, CU-278, CU-280, and CU-281 with CU-242, CU-271, CU-265, and CU-264, respectively). The electronic properties of the R groups did not affect compound activity based on the available data. The addition of electron-withdrawing, electron-donating, and electron-neutral groups did not have a clear and consistent effect on activity. Although there are no direct comparisons, cyclization of compounds (e.g. CU-262 and CU-282) did not significantly alter the potency compared with non-cyclized compounds (e.g. CU-264, CU-265, CU-280, and CU-281). - SAR studies of N-(quinolin-8-yl)benzenesulfonamides revealed 3 compounds with sub-micromolar potencies for sAPPβ reduction. The most potent compound, CU-264, is further evaluated.
- The previously described hit was further analyzed in physiologically relevant systems, e.g. primary neurons and Alzheimer's model mice. Two complementary neuronal cell systems were employed to test the effects of candidate compounds on various aspects of APP processing: cultured mouse cortical neurons (postnatal day 0) infected with recombinant lentivirus carrying human APPsw (Lenti-APPsw;
FIG. 11 ); and cultured cortical neurons prepared from Tg2576 mice (carrying human APPsw transgene under the control of the PrP promoter). Lenti-APPsw infected cortical neurons can be prepared in a relatively large scale, but suffer from variability in lentiviral infection efficiency, resulting in variable levels of APP expression. In contrast, cortical neurons derived from Tg2576 provide constant APP expression. However, neuronal yield is generally much lower, since only half the pups will contain the transgene when heterozygote crossbreeds were conducted. Therefore, Initial characterization experiments were performed using cortical neurons infected with Lenti-APPsw. Compounds exhibiting inhibitory activity on sAPPβ and/or Aβ would then be re-evaluated in Tg2576 mice-derived neurons. - Ex vivo and in vivo assays will be used to characterize certain hit(s). Ex vivo systems, such as organotypic brain slices, offer an alternative to in vivo assays, and can also be used to test a large number of compounds. Further more, at least with regard to the Aβ release phenotype, brain slice data have been shown to correlate well with the results obtained in vivo (reviewed in Noraberg et al., 2005). Brain slices from p7 Tg2576 pups are used herein for compound characterization.
- For in vivo studies, interstitial fluid (ISF) compound administration and Aβ measurement, as well as intraperitoneal (IP) compound injection, both utilizing Tg2576 mice, will be used to characterize compounds. Positioning of a guide cannula to the mouse hippocampus allows for insertion of a microdialysis apparatus, which can be used to infuse compounds at multiple concentrations sequentially in the awake mouse. Aβ measurements can be performed using the same apparatus, yielding rapid dose-response determinations (Cirrito et al., 2003). This method allows for rapid assessment of compound effect on AP on a dynamic time scale. More conventionally, compounds can also be administered via IP injection. For these experiments, 12-month old Tg2576 mice will be used.
- CU-264 does not Reduce Aβ40 in Lenti-APPsw Infected Primary Cortical Neurons
- Lenti-APPsw infected primary cortical neurons were used for the initial round of physiological experiments. Primary cortical neurons were harvested from wild-type P0 pups using established protocols. The majority of cells from the resulting culture exhibit neuronal morphology on light microscopy and express neuronal β-tubulin as visualized by immunocytochemistry using the TUJ1 antibody (Covance,
FIG. 12 ). - The Lenti-APPsw vector was co-transfected into HEK293 T cells with ViraPower packaging mix (Invitrogen) to generate the lentivirus. Lentiviral-mediated transduction of APPsw in primary neurons was performed by adding neuron primary culture media containing the lentiviral particles to wild-type DIV-14 primary neurons (
FIG. 11 ). After 24 hours, neurons were incubated with media for 72 hours prior to collecting for Aβ40 measurement. Two batches of virus (LV-1 and LV-2) were tested, showing that there is batch-to-batch variation in the viral titer. - Using this experimental paradigm, CU-264 was tested at 10 and 2 μM concentrations to examine the sAPPβ- and Aβ-lowering activity of the compound. The protocol was modified slightly to allow for 24-hour compound treatment. DIV-14 wild-type primary neurons (
FIG. 12 ) cultured on 6-well plates were incubated for 24 hours with primary culture media containing lentiviral particles. After infection, fresh media was mixed in a 1:1 ratio with conditioned media collected prior to lentiviral infection, and applied to the cells for 48 hours to allow for APP expression. At the end of this “pre-drug” incubation, media containing compound was applied for 24-hour treatment. Control experiments using DMSO alone showed that media collected after the 24-hour treatment period contained at least two times higher Aβ40 than that collected just after the 48-hour pre-drug period. CU-264, which exhibited sub-micromolar potency for sAPPβ reduction in SY5Y-BACEGFP-SEAPAPPwt cells, did not reduce Aβ40 in primary neurons (FIG. 13A ). In contrast, CU-264 was observed to increase AP at 10 μM. - The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
- Patents, patent applications, publications, product descriptions, GenBank Accession Numbers, and protocols are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties for all purposes.
Claims (18)
1. A composition comprising a compound of Formula I:
wherein R1, R2, R3, R4, and R5 are independently selected for each occurrence from the group consisting of hydrogen, halogen, alkyl, aryl, alkoxy, aryloxy, alkylthiol, arylthiol, CN, and NO2; and
wherein R10 is selected from the group consisting of substituted or unsubstituted alkyl, cycloalkyl, aryl, heteroaryl and alkenyl.
2. The composition of claim 1 , wherein R1, R2, R3, R4, and R5 are independently selected for each occurrence from the group consisting of:
hydrogen, methyl, Cl, OCH3, CF3 and F.
3. The composition of claim 1 , wherein R10 is selected from the group consisting of phenyl, 2-Nitrophenyl, 3-Nitrophenyl, 4-Nitrophenyl, 4-Methyl-2-nitrophenyl, 2-Methyl-5-nitrophenyl, 2-Nitro-4-(trifluoromethyl)phenyl, 4-Methoxy-2-nitrophenyl, 2-Methyl-5-nitrophenyl, 4-Methyl-2-nitrophenyl, 4-Methylphenyl, 2-Aminophenyl, 2-Amino-4-methyl phenyl, Thiophen-2-yl, 5-Chlorothiophen-2-yl, 5-Bromothiophen-2-yl.
4-9. (canceled)
10. A method for inhibiting the activity of a β-site APP cleavage enzyme 1 (BACE1) in a cell which comprises contacting the cell with a compound of claim 1 in an amount effective to inhibit β-site APP cleavage enzyme 1 activity.
11. The method of claim 10 , wherein the inhibition of β-site APP cleavage enzyme 1 activity reduces the metabolism of an amyloid precursor protein (APP).
12. The method of claim 10 , wherein the cell is a mammalian cell.
13. The method of claim 10 , wherein the cell is contacted in vitro.
14. A method for treating Alzheimer's disease in an individual, which method comprises administering to the individual an effective amount of a compound according to claim 1 .
15. A method for inhibiting the activity of a Nuclear factor-κ B (NFκB) in a cell which comprises contacting the cell with a compound of claim 1 in an amount effective to inhibit Nuclear factor-κ B (NFκB) activity.
16. The method of claim 15 , wherein the inhibition of Nuclear factor-κ B (NFκB) activity reduces nuclear translocation of the Nuclear factor-κ B (NFκB).
17. The method of claim 15 , wherein the cell is a mammalian cell.
18. The method of claim 15 , wherein the cell is contacted in vitro.
19. A method for treating a disease related to dysfunction of cell proliferation, the immune system, and/or inflammation in an individual, which method comprises administering to the individual an effective amount of a compound according to claim 1 .
20. The method of claim 19 , wherein the disease is cancer.
21. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
22. The composition of claim 1 , wherein R10 is a substituted phenyl, and wherein the substituents are selected from the group consisting of hydrogen, halogen and combinations thereof.
23. The composition of claim 22 , wherein the substituents are selected from the group consisting of hydrogen, fluorine, chlorine and combinations thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/223,967 US20140275165A1 (en) | 2008-10-30 | 2014-03-24 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10989108P | 2008-10-30 | 2008-10-30 | |
US14340409P | 2009-01-08 | 2009-01-08 | |
US14353209P | 2009-01-09 | 2009-01-09 | |
PCT/US2009/043011 WO2010051064A1 (en) | 2008-10-30 | 2009-05-06 | COMPOUNDS THAT INHIBIT NFκB ACTIVITY |
US13/094,504 US8685963B2 (en) | 2008-10-30 | 2011-04-26 | Compounds that inhibit NFκB and BACE1 activity |
US14/223,967 US20140275165A1 (en) | 2008-10-30 | 2014-03-24 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/094,504 Continuation US8685963B2 (en) | 2008-10-30 | 2011-04-26 | Compounds that inhibit NFκB and BACE1 activity |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140275165A1 true US20140275165A1 (en) | 2014-09-18 |
Family
ID=42129180
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/094,504 Expired - Fee Related US8685963B2 (en) | 2008-10-30 | 2011-04-26 | Compounds that inhibit NFκB and BACE1 activity |
US14/223,967 Abandoned US20140275165A1 (en) | 2008-10-30 | 2014-03-24 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/094,504 Expired - Fee Related US8685963B2 (en) | 2008-10-30 | 2011-04-26 | Compounds that inhibit NFκB and BACE1 activity |
Country Status (2)
Country | Link |
---|---|
US (2) | US8685963B2 (en) |
WO (1) | WO2010051064A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210323924A1 (en) * | 2015-11-28 | 2021-10-21 | Russell Dahl | Quinoline sulfonamides useful to treat disease |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120214803A1 (en) * | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
WO2012122534A2 (en) * | 2011-03-10 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation |
US10030048B2 (en) * | 2014-09-26 | 2018-07-24 | Rajendra Sahai Bhatnagar | Inhibitors of NF κ-B activity for treatment of diseases and disorders |
AU2018391531B2 (en) * | 2017-12-20 | 2024-01-18 | Otago Innovation Limited | Quinoline sulfonamide compounds and their use as antibacterial agents |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060041006A1 (en) * | 2004-05-06 | 2006-02-23 | Ibrahim Prabha N | PDE4B inhibitors and uses therefor |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4253865A (en) * | 1979-09-06 | 1981-03-03 | Chevron Research Company | 1,1-Dioxo-2-halohydrocarbylthio-1,2-benzoisothiazolidines |
US4369320A (en) * | 1980-11-03 | 1983-01-18 | E. I. Du Pont De Nemours And Company | N-[Heterocyclicaminocarbonyl]-8-quinolinesulfonamides |
WO1991018891A1 (en) | 1990-06-04 | 1991-12-12 | Pfizer Inc. | Aromatic pyrrolidine and thiazolidine amides |
CA2313828A1 (en) * | 2000-08-01 | 2002-02-01 | Institut De Recherches Cliniques De Montreal/Ircm | Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production |
EP1406884A1 (en) * | 2001-05-11 | 2004-04-14 | Biovitrum Ab | Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
US20030082140A1 (en) | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
US7332508B2 (en) | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
WO2004099106A2 (en) | 2003-05-05 | 2004-11-18 | New York University | Facilitated forward chemical genetics using tagged triazine library |
US20050282879A1 (en) | 2004-06-17 | 2005-12-22 | Foad Salehani | Methods and composition for treatment of migraine and symptoms thereof |
EP1888060A2 (en) * | 2005-05-24 | 2008-02-20 | A. T. Still University of Health Sciences | Nk-b inhibitors for the treatment of muscular dystrophy |
WO2008008463A2 (en) | 2006-07-14 | 2008-01-17 | Trustees Of Columbia University In The City Of New York | METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPβ |
-
2009
- 2009-05-06 WO PCT/US2009/043011 patent/WO2010051064A1/en active Application Filing
-
2011
- 2011-04-26 US US13/094,504 patent/US8685963B2/en not_active Expired - Fee Related
-
2014
- 2014-03-24 US US14/223,967 patent/US20140275165A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060041006A1 (en) * | 2004-05-06 | 2006-02-23 | Ibrahim Prabha N | PDE4B inhibitors and uses therefor |
US7585859B2 (en) * | 2004-05-06 | 2009-09-08 | Plexxikon, Inc. | PDE4B inhibitors and uses therefor |
Non-Patent Citations (1)
Title |
---|
Pubchem (2007, ChemBL256609) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210323924A1 (en) * | 2015-11-28 | 2021-10-21 | Russell Dahl | Quinoline sulfonamides useful to treat disease |
Also Published As
Publication number | Publication date |
---|---|
US8685963B2 (en) | 2014-04-01 |
US20120064099A1 (en) | 2012-03-15 |
WO2010051064A1 (en) | 2010-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2497809C2 (en) | Naphthalene carboxamide derivatives as protein kinase and histone deacetylase inhibitors, methods for preparing and using them | |
US20140275165A1 (en) | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY | |
JP2019108346A (en) | Inhibitor of lysine-specific demethylase-1 | |
US20110071124A1 (en) | Compounds that Inhibit Production of sAPPB and AB and Uses Thereof | |
JP5747142B2 (en) | Pharmaceutical composition containing a compound that inhibits DYRK | |
WO2017157322A1 (en) | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and users thereof | |
JP2009535320A (en) | N- (2-thiazolyl) amide derivatives as GSK-3 inhibitors | |
CN106748922B (en) | A kind of novel sulfone acid derivative, preparation method and its purposes as drug | |
EP2582670B1 (en) | Piperidinyl compound as a modulator of chemokine receptor activity | |
CN108250058B (en) | PPAR agonists and their use in the treatment of Alzheimer's disease and other diseases | |
WO2010129620A1 (en) | Imidazo [ 1, 2 -a] pyridin-2 -yl-phenyl derivatives to be used in cancer treatment | |
Gao et al. | Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β) | |
WO2010085799A2 (en) | Compositions and method for the treatment of parkinson's disease | |
Sheng et al. | Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1, 2, 4-oxadiazole derivatives | |
WO2013183718A1 (en) | Screening method, protein instability and/or stability inducers, and protein activity assesment | |
KR20040035841A (en) | Chemical compounds | |
AU2019208634B2 (en) | Dihydroindolizinone derivative | |
JP2018087173A (en) | Anti-malignant brain tumor therapeutic agent | |
CN110229146B (en) | Histone deacetylase inhibitor and preparation method and application thereof | |
EP3998107A1 (en) | Method for producing insulin-producing cell using dihydroindolizinone derivatives | |
CN109305972B (en) | Dihydropyranopyrazole compound and preparation method and application thereof | |
KR102385742B1 (en) | Novel 4-Oxoquinazoline-Based N-Hydroxypropenamides and its use | |
KR102042778B1 (en) | Novel sodium channel inhibitor compound, preparation method thereof, and pharmaceutical composition for prevention or treatment of sodium channel related diseases containing the same as an active ingredient | |
WO2023248255A1 (en) | Beta carboline analogues as selective and biased kappa opioid receptors agonists for treating various associated pathophysiological conditions | |
WO2023041905A1 (en) | Aminopyridines as activators of pi3 kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANDRY, DONALD W.;KIM, TAE-WAN;DENG, SHI XIAN;AND OTHERS;SIGNING DATES FROM 20110520 TO 20110715;REEL/FRAME:032516/0224 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |